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Abstract 
Tuberculosis is caused by Mycobacterium tuberculosis, an intracellular pathogen that can survive in 
host cells, mainly in macrophages. An increase of multidrug-resistant tuberculosis qualifies this infectious 
disease a major public health problem worldwide. The cellular uptake of the antimycobacterial agents by 
infected host cells is limited. Our approach is to enhance the cellular uptake of the antituberculars by target 
cell-directed delivery using drug-peptide conjugates to achieve an increased intracellular efficacy. In this 
study, salicylanilide derivatives (2-hydroxy-N-phenylbenzamides) with remarkable antimycobacterial 
activity were conjugated to macrophage receptor specific tuftsin based peptide carriers through oxime bond 
directly or by insertion of a GFLG tetrapeptide spacer. We have found that the in vitro antimycobacterial 
activity of the salicylanilides against M. tuberculosis H37Rv is preserved in the conjugates. While the free 
drug was ineffective on infected macrophage model, the conjugates were active against the intracellular 
bacteria. The fluorescently labelled peptide carriers that were modified with different fatty acid side chains 
showed outstanding cellular uptake rate to the macrophage model cells. The conjugation of the 
salicylanilides to tuftsin based carriers reduced or abolished the in vitro cytostatic activity of the free drugs 
with the exception of the palmitoylated conjugates. The conjugates degraded in the presence of rat liver 
lysosomal homogenate leading to the formation of an oxime bond-linked salicylanilide-amino acid fragment 
as the smallest active metabolite. 
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OT10:  dituftsin derivative, [TKPKG]2 
OT20:  tetratuftsin derivative, [TKPK]4 
pal:  palmitoyl side chain 
SAL:  salicylanilide derivative 
T5:  monotuftsin derivative, TKPKG 
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1. Introduction 
One third of the world’s population is estimated to be infected with tuberculosis (TB), which is an 
infectious disease caused by the slow growing Mycobacterium tuberculosis bacteria. M. tuberculosis is 
mainly an intracellular pathogen; in the latent form of TB the bacteria can survive within the host cell 
phagocytes for many years. Latent TB is an asymptomatic phase of the disease, during this dormant phase 
the bacteria do not multiply but persist within their host cells (monocytes, macrophages). People infected 
with latent TB have a lifetime risk of 10% of developing active TB. However, persons with compromised 
immune systems have a much higher risk of falling ill [1]. The treatment of TB is long and the currently used 
antituberculars have serious side effects. 
The increase of multidrug-resistant tuberculosis (MDR-TB) in the last decade is very alarming. MDR-
TB strains are resistant to at least isoniazid (INH) and rifampicin (RIF), the two most effective first-line 
antituberculars. Growing number of XDR-TB (extensively drug-resistant TB; resistant to INH, RIF, any 
fluoroquinolone, and one of the three second-line injectables, amikacin, capreomycin, or kanamycin) was 
also reported [1]. 
In addition, the appearance of a new emerging mycobacterium, Mycobacterium abscessus has been 
identified. M. abscessus is an intracellular pathogen that is the most chemotherapy-resistant rapid-growing 
mycobacterium.  It is a common water contaminant, responsible for a wide spectrum of infectious diseases, 
chronic lung disease in patients with cystic fibrosis, post-traumatic wound infections, soft tissue infections 
and disseminated cutaneous diseases, mostly in patients with suppressed immune system. The treatment of 
M. abscessus infections is difficult, high rate of intrinsic resistance can occur to both antitubercular drugs 
and to most of the available antibiotics [2, 3, 4, 5]. 
There is an urgent need to try to overcome these threatening mycobacterial strains by the development 
of new potent antimycobacterial drugs with enhanced activity in the intracellular environment.   
Salicylanilides (2-hydroxy-N-phenylbenzamides) have been the subject of interest in medicinal 
chemistry for many years. They have a wide variety of interesting biological activities, including 
antimycobacterial effects [6]. They have shown activity not only against classical M. tuberculosis H37Rv, but 
also against atypical strains of mycobacteria, mainly Mycobacterium avium, M. fortuitum and M. kansassii 
where standard antituberculotics fail [6, 7]. Importantly, salicylanilides inhibit the growth of different MDR 
and XDR TB strains [8, 9]. In our previous study we reported salicylanilide derivatives that are highly 
effective also against M. abscessus [9]. The structure-activity relationship studies suggest that among the big 
family of the different salicylanilides the derivatives substituted with halogens on both salicylic and aniline 
ring are the most potent ones against mycobacteria [6, 9].  
Salicylanilides have probably multiple mechanisms of action. They were identified as inhibitors of the 
two-component regulatory systems of bacteria, which is a signal transmission pathway involved in the 
maintenance of bacterial cell homeostasis and the expression of virulence factors [10]. Salicylanilides have 
displayed the ability to inhibit various bacterial enzymes, e.g., mycobacterial isocitrate lyase [8, 11, 12, 13, 
14] and methionine aminopeptidase [14].  
Unfortunately, in many cases the outstanding antimycobacterial activity of the salicylanilide 
derivatives is overshadowed by their high or moderate cytotoxicity to mammalian cells (human monocytic 
cells) [9]. 
The design of peptide-based drug conjugates is one of the approaches that can promote increased drug 
specificity, where the peptide component serves as selective target and carrier to infected macrophages. With 
the drug delivery systems enhanced cellular uptake and bioavailability, controlled drug release and reduced 
side effects can be achieved. Receptor mediated endocytosis can enhance the intracellular elimination of M. 
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tuberculosis [15, 16]. Receptors that are expressed mainly on macrophages could be a proper target to 
achieve more efficient inhibition of M. tuberculosis from infected macrophages. In previous works tuftsin 
receptor is used for targeted drug delivery to macrophages [17, 18, 19]. It is estimated that there are 72 000 
tuftsin binding sites on the surface of phagocytic cells [20], therefore tuftsin can be a promising carrier 
peptide for targeted delivery into macrophages through receptor mediated internalization [17, 21].  
Tuftsin is a natural tetrapeptide (human: TKPR; canine: TKPK) produced by enzymatic cleavage of 
the Fc-domain of the heavy chain of immunoglobulin G (IgG) by two enzymes, leukokininase and spleen 
tuftsin endocarboxypeptidase. This peptide activates several components of the immune system, including 
granulocytes and macrophages [22]. Tuftsin derivatives also stimulates phagocytosis and cell migration [23], 
human tuftsin and its analogues have a chemotactic effect on monocytes [24, 25]. 
During the past years, a new group of sequential oligopeptides based on tuftsin has been developed in 
our laboratory. The oligotuftsin derivatives consist of tandem pentapeptide repeat units [TKPKG]n (n: 2, 4, 6, 
8) derived from the canine tuftsin sequence TKPK extended by a C-terminal Gly [26, 27]. These compounds 
are nontoxic, nonimmunogenic, biodegradable, and exhibit tuftsin-like biological properties, e.g. 
immunostimulatory activity and chemotactic activity on monocytes [28, 29]. The canine tuftsin TKPK where 
arginine is replaced by lysine that has also basic character has similar biological activities like the human 
tuftsin TKPR [30]. However, the second lysine residue in the sequence of TKPK can offer a new functional 
group for connection of a biologically active compound. With the addition of a glycine residue to the C-
terminal of TKPK racemization free condensation of the fragments can be achieved to form larger oligomers 
[26]. Molecular modeling study suggested a flexible structure for oligotuftsin OT20 ([TKPKG]4), and also 
demonstrated fairly good solvent accessibility of the ε-amino group of each lysine residue, 4Lys was the most 
accessible out of the eight Lys residues [26]. 
Modifying drug-peptide conjugates with fatty acids can be a promising tool to improve their activity.  
It was found that conjugation of fatty acids with different lengths modulated the antibacterial activity of 
cationic peptides and antimicrobial peptides [31, 32]. Attaching a hydrophobic moiety to a drug-peptide 
conjugate can play an important role in the interaction of the drug and lipid membranes [33]. Palmitic, 
hexadecenoic, octadecenoic and tuberculostearic acids were found as the major fatty acid constituents of 
phospholipids of Mycobacteria [34]. Daptomycin is a decanoic acid containing lipopeptide antibiotic that 
displays rapid bactericidal activity against Gram-positive pathogens, including streptococci, methicillin-
resistant S. aureus, and vancomycin-resistant enterococci [35]. Daptomycin disrupts bacterial cell membrane 
function and permeability [36].  
INH-tuftsin conjugates GTKPK(INH-CH2-CO)G and [TKPK(INH-CH2-CO)G]4 were effective against 
M. tuberculosis and the minimal inhibitory concentration values were comparable to the free INH moiety 
[37]. Enhanced cellular uptake and significant inhibition of intracellular M. tuberculosis was performed by 
conjugation of new in silico identified drug candidate to [TKPKG]4 tuftsin derivative (TB5-OT20) [38]. 
Tuftsin based conjugates of pyridopyrimidine derivatives with in vitro antitubercular activity presented 
increased membrane affinity on lipid model systems [39]. Palmitoylated tuftsin conjugate of INH (pal-
T5(INH)2, where T5 is TKPKG) and new in silico identified drug candidate (pal-T5(TB820)2) found to be 
effective against susceptible and multiresistant M. tuberculosis strains with a relatively high in vitro 
selectivity [40, 41]. Free INH did not exhibit intracellular antitubercular activity, in contrast, its pal-
T5(INH)2 conjugate significantly inhibited the intracellular M. tuberculosis [42]. The palmitoylated 
conjugates were encapsulated into PLGA (poly(lactide-co-glycolide)) nanoparticles with high encapsulation 
efficacy and the encapsulated compound showed high in vivo efficacy and low toxicity [41, 42]. 
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In this study various tuftsin derivatives such as tetramer [TKPKG]4 (OT20), heterotrimer TKPR-
[TKPKG]2 (TKPR-OT10), dimer [TKPKG]2 (OT10) and monomer tuftsin derivatives TKPKG (T5), TKPR, 
TKPPR (tuftsin antagonist [43]) were used as carrier peptides. Tuftsin derivatives with modified Lys 
residues (e.g. introduction of palmitic acid, decanoic acid or butyric acid) were also studied. Modification 
with fatty acid chains can enhance the lipophilicity, membrane affinity and encapsulation efficacy [33, 41, 
42].  Modified conjugable salicylanilides were attached to the tuftsin derivatives via oxime bond directly or 
by the insertion of a spacer between the drug molecule and the carrier. The oxime bond is chemically stable 
between pH 3 and 8 [44], the incorporation of an enzymatic cleavable spacer between the drug and the 
carrier moiety might be necessary for the efficient drug release and activity. As spacer, the enzyme labile 
GFLG tetrapeptide was applied, which could be cleaved by the lysosomal cysteine protease, cathepsin B 
[45]. Here we report the synthesis, chemical characterization, in vitro extracellular and intracellular 
antimycobacterial activity, cytotoxic and cytostatic activity, cellular uptake, membrane integrity studies and 
lysosomal degradation of salicylanilide-tuftsin conjugates. 
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2. Results and Discussion 
 
2.1. Chemistry 
 
2.1.1. Synthesis of the salicylanilide derivatives SAL1-3 
Salicylanilides were prepared by the reaction of the appropriate substituted salicylic acids and the 
substituted anilines in the presence of phosphorus trichloride (0.5 eq.) in chlorobenzene (Scheme 1). The 
reaction was carried out in a microwave reactor for 22 min to reflux [46]. The yields ranged from 6-7 %. The 
yields are low due to the predominant formation of Schiff bases instead of amide. In the case of the synthesis 
of SAL1 and SAL2, the resulting Schiff base (main product) can react with other molecules of 4-
acetylaniline to form more complex Schiff bases. 
 
    
 
Scheme 1. Synthesis of conjugable salicylanilides SAL1-3 (Ph-Cl: chlorobenzene). 
 
2.1.2. Synthesis of the tuftsin derivatives 
Tuftsin derivatives were synthesized using the standard Fmoc/tBu strategy. The C-terminal of the 
peptides was obtained in amide or carboxyl form after cleavage. In the short name of the peptides or 
conjugates only the carboxyl form C-terminal is indicated, otherwise the C-terminal of the peptides or 
conjugates are in amide form. The synthesis of the tuftsin derivatives without side chain modification is 
summarized in the Supporting Information Scheme S1.  
In the case of the peptides with modified Lys side chain the routinely used Fmoc-Lys-tert-
butoxycarbonyl-OH (Fmoc-Lys(Boc)-OH) was replaced by Fmoc-Lys(Dde)-OH in the appropriate position 
and after the selective removal of the Dde group with a solution of 2% hydrazine hydrate in DMF [47] the 
synthesis was carried on with the desired modification (coupling of fatty acids, Boc-Aoa-OH or 5(6)-
carboxyfluorescein). The schematic route of the synthesis of the tuftsin derivatives with side chain 
modification is summarized in Scheme 2. 
The N-terminal of most of the peptides were (aminooxy)acetylated for the conjugation (Aoa-tuftsin 
derivatives). Control peptides with acetylated N-termini were also prepared (Ac-tuftsin derivatives). 
Fluorescently labelled peptides with 5(6)-carboxyfluorescein at the N-termini was also synthesized (Cf-
tuftsin derivatives). All peptides were cleaved from the resin with TFA in the presence of appropriate 
scavengers. The Aoa-peptides were used for conjugation without purification. The acetylated control 
peptides and the fluorescently labelled peptides were purified using semi-preparative RP-HPLC. All tuftsin 
 8 
 
derivatives were chemically characterized by analytical RP-HPLC, mass spectrometry (Supporting 
Information Table S1) and amino acid analysis (data not shown). 
 
 
Scheme 2. Schematic route of the synthesis of the tuftsin derivatives with side chain modification. 
 
2.1.3. Synthesis of the salicylanilide-tuftsin conjugates 
SAL1, SAL2 and SAL3 were conjugated to the (aminooxy)acetylated tuftsin derivatives by oxime 
ligation, which was carried out under acidic condition (pH 4.5) in a mixture of sodium acetate buffer solution 
and 2-methoxyethanol (Scheme 3A). In the case of SAL3 the reaction occurred faster due to the higher 
reactivity of the aldehyde group compared to the acetyl group. The conjugation was monitored using 
analytical RP-HPLC (Supporting Information Figure S1). The general structures of the synthesized 
conjugates are schematically represented in Scheme 3B. The schematic figure of all of the salicylanilide-
tuftsin conjugates are represented in Supporting Information Figure S2. The conjugates were purified using 
semi-preparative RP-HPLC and chemically characterized by analytical RP-HPLC, mass spectrometry and 
amino acid analysis. All purified conjugates demonstrated a single peak on analytical RP-HPLC with a mass 
coinciding with the theoretically calculated molecular mass (Supporting Information Table S2). The amino 
acid composition of the conjugates was proved by amino acid analysis where the accuracy was less than 5% 
(data not shown). 
The stability of the conjugates was investigated in the condition of the in vitro studies. The stability 
was studied in DMSO at 4 °C, in Sula semisynthetic medium (pH 6.5) at 37 °C, in serum free RPMI-1640 
cell culture medium at 37 °C, and in complete RPMI-1640 cell culture medium at 37 °C using analytical RP-
HPLC and mass spectrometry (methods and conditions are in the Supporting Information). The compounds 
were stable in DMSO at 4 °C at least for 3 weeks (Figure S3). They are mostly stable in Sula medium after 4 
weeks of incubation, only approximately 5% of the conjugate was decomposed to the free salicylanilide and 
2-hydroxyacetyl-tuftsin derivative (Figure S4-S5). The compounds were stable in serum free and in complete 
cell culture medium at 37 °C at least for 1 week and 1 day respectively (Figure S6-S7). 
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Scheme 3. (A) Conjugation of salicylanilide derivatives to (aminooxy)acetylated tuftsin derivatives and (B) 
the summarized schematic structure of the salicylanilide-tuftsin conjugates. 
 
2.1.4. Synthesis of salicylanilide-amino acid derivatives 
To investigate the in vitro activity of the smallest metabolites produced during the degradation in the 
lysosomal homogenate, SAL2-Aoa-Thr-OH and SAL2-Aoa-Gly-OH were synthesized. To estimate 
lipophilicity profile for tuftsin conjugates three salicylanilide-amino acid derivatives were used as reference 
compounds with calculated logP values (Table S3):  SAL2-Aoa-Thr-OH, SAL2-Aoa-Gly-OH and H-
Lys(SAL2-Aoa)-OH (SAL2 is on the ε-amino group of the lysine). The amino acids were functionalized 
with (aminooxy)acetyl group on solid phase. After cleavage from the resin Aoa-Thr-OH, Aoa-Gly-OH and 
H-Lys(Aoa)-OH (Table S1) was conjugated to SAL2 salicylanilide derivative as described above. The 
SAL2-amino acid derivatives were purified using semi-preparative RP-HPLC and chemically characterized 
by analytical RP-HPLC and mass spectrometry (Table S2). 
 
2.1.5. Lipophilicity profile of the salicylanilide derivatives and salicylanilide-peptide conjugates 
Lipophilicity is an important physicochemical parameter regarding the interaction between an active 
compound and membrane structures of the cells. It has been studied that the retention of a compound on 
reversed-phase chromatographic columns (C18) resulted in correlation with the lipophilicity of the 
compounds [48, 49]. To predict lipophilicity of peptides experimentally or semiempirically is difficult, since 
amino acid side chains contain charged or uncharged polar and non-polar groups and have a range of size 
and flexibility. However, retention time (Rt) on the reversed phase columns may provide relevant 
information about the lipophilicity range of compounds such as drug candidates and their peptide conjugates 
[50, 51]. The behaviour of a compound in RP-HPLC system depends on its interactions with the non-polar 
stationary phase: the more lipophilic a compound is, the stronger its retention on the column. 
A 
B 
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The lipophilicity of the representative compounds was estimated by the retention time acquired on 
analytical RP-HPLC system using a C18 column and the same gradient for each compounds (Figure 1, Table 
S3). Parent salicylanilides from our previous work (2a-d) [9] are also presented for the comparison with the 
conjugable salicylanilide derivatives (SAL1-3). The oxime bond containing salicylanilide-amino acid 
derivatives detected during the lysosomal hydrolysis of the conjugates and representative conjugates are also 
included. The calculated logP values of the reference salicylanilide derivatives and salicylanilide-amino acid 
derivatives obtained by CS ChemOffice Ultra ver. 11.0 are also presented (Figure 1, Table S3).  
According to the retention time of the compounds, the parent salicylanilides are the most lipophilic 
molecules followed by the conjugable salicylanilides (Figure 1, Table S3). The salicylanilide-amino acid 
derivatives are less lipophilic than the conjugable salicylanilides. Tuftsin derivatives are peptides with 
charged amino acid side chain moieties (Lys, Arg) therefore they possess high hydrophilic character. The 
conjugation of the salicylanilide to peptide made the conjugates more lipophilic than the carrier tuftsin 
peptide itself. The longer, tetratuftsin-conjugate is more hydrophilic, than the di- or monotuftsin derivatives 
(SAL2-Aoa-OT20 Rt: 14.3 min, SAL2-Aoa-OT10 Rt: 14.9 min, SAL2-Aoa-T5 15.6 min). Conjugate with 
the GFLG spacer built up by non-polar amino acids has more lipophilic character than its analogue without 
the spacer (SAL2-Aoa-OT20 Rt: 14.3 min, SAL2-Aoa-GFLG-OT20 Rt: 15.7 min). The different fatty acid 
side chain modifications also altered the lipophilicity of the conjugate as was expected; the longer the fatty 
acid is, the more lipophilic the molecule (SAL2-Aoa-OT20: Rt: 14.3 min, SAL2-OT20(4-but) Rt:14.7 min, 
SAL2-Aoa-OT20(4-dec) Rt: 16.4 min SAL2-Aoa-OT20(4-pal) Rt: 18.4 min). The position of the palmitic 
acid side chain influences the lipophilicity. In the SAL2-Aoa-OT20(4-pal) conjugate (Rt: 18.4 min), where 
the non-polar moieties such as the SAL2 and the palmitoyl side chain are closer to each other, the retention 
time is higher than in the case of the SAL2-Aoa-OT20(14-pal) (Rt: 17.3 min), where the palmitic acid is 
further from the SAL2 molecule in the sequence. The effect of the fatty acids is more significant in the case 
of the monotuftsin conjugate; SAL2-Aoa-T5(4-dec) has similar lipophilicity as the SAL2, moreover the 
SAL2-Aoa-T5(4-pal) monotuftsin conjugate is more lipophilic than the SAL2 and any other presented 
salicylanilides. The number of the drug molecules in the conjugate also influences the lipophilicity, the two 
SAL2 containing conjugate has higher lipophilicity than the one SAL2 containing conjugate (SAL2-Aoa-
OT20(4-SAL2-Aoa) Rt: 16.3 min, SAL2-Aoa-OT20 Rt: 14.3 min).  
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Figure 1. Retention time of parent salicylanilides, conjugable salicylanilides, salicylanilide amino acid 
derivatives (metabolites detected during lysosomal degradation) and salicylanilide-peptide conjugates. The 
calculated logP value is indicated in the case of the parent salicylanilides, conjugable salicylanilides and 
metabolites using the program CS ChemOffice Ultra ver. 11.0 (CambridgeSoft, Cambridge, MA, USA). 
LogP was calculated for the amino acid derivatives with protonated amino group and/or deprotonated 
carboxylic group. The C-terminal of the peptides is in amide form, Ac = acetyl, retention time (Rt) was 
obtained on Exformma HPLC system; column: Agilent Zorbax SB-C18, 5 μm, 4.6mmx150mm, 100Å; 
gradient: 0 min 0% B, 5 min 0% B, 15 min 60% B, 25  min 100% B; eluents: 0.1% TFA in water (A) and 
0.1% TFA in acetonitrile-water (80:20, v/v) (B); flow rate: 1 mL/min; detection at 220 nm. 
 
2.2. In vitro antimycobacterial activity 
The free salicylanilide derivatives and the salicylanilide-tuftsin conjugates were evaluated for their in 
vitro antimycobacterial activity against two strains of slowly growing M. tuberculosis: the sensitive H37Rv 
and the multidrug resistant A8 MDR strain (resistant to both INH and RIF, two first-line antituberculars) and 
against a fast growing mycobacterium, the M. abscessus strain. Isoniazid (INH), ciprofloxacin (CIPX) and 
gentamicin (GEN) as antimycobacterial active drugs were involved for comparison. Table 1 reports the 
obtained minimum inhibitory concentrations (MICs). The inhibition was confirmed using Löwenstein-Jensen 
solid media and the colony forming units (CFU) were determined. The colony forming units are presented in 
the Supporting Information Table S4. 
The MIC values of previously published parent salicylanilides are presented in Table 2 for comparison 
[9]. These parent salicylanilides have outstanding in vitro antimycobacterial activity. They have MICs from 
1.4-2.8 μM against M. tuberculosis H37Rv and A8 MDR and their MICs against M. abscessus range from 
3.2-13.9 μM. The introduction of the carbonyl group into the molecule reduced their in vitro 
antimycobacterial activity. In the parent salicylanilides both the salicylic acid ring and the aniline ring 
contain halogen substituents. In SAL1 and SAL2 the halogen on the aniline ring was replaced by an acetyl 
group though SAL1 and SAL2 still have an appropriate inhibition activity against M. tuberculosis H37Rv (8.6 
and 7.5 μM respectively). Their MIC values against the resistant strain are slightly higher (SAL1 17.3 μM, 
SAL2 15.0 μM) than the MIC values of the parent molecules. Against M. abscessus the new salicylanilides 
SAL1 and SAL2 are effective with higher MIC values (34.5 and 59.8 μM respectively). In the case of SAL3, 
where the halogen group of the salicylic acid ring was replaced by an aldehyde group, the in vitro 
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antimycobacterial activity decreased significantly against all the three bacterial strain compared to the parent 
salicylanilides and to SAL1 and SAL2.   
The in vitro antimycobacterial activity of the salicylanilides is preserved in the conjugates against M. 
tuberculosis H37Rv although their MIC values (20.3-186.5 μM) are higher than the MIC of the free 
salicylanilides (7.5-25.9 μM). There is no difference in the activity between the different salicylanilide 
containing OT20 or OT20(4-pal) conjugates. In terms of the peptide length, SAL2-Aoa-OT20 showed better 
activity than the shorter SAL2-Aoa-OT10 and the shortest SAL2-Aoa-T5 showed the best efficacy with very 
low MIC values (21.8 μM) among these conjugates. The incorporation of the enzyme labile GFLG spacer 
has no significant benefit in the antimycobacterial activity of the conjugates, the MIC values of the one 
tuftsin unit containing conjugates with or without spacer is mostly the same. In the case of tetratuftsin 
derivative containing conjugate the presence of the GFLG spacer reduce its activity (SAL2-Aoa-OT20 with 
MIC of 81.5 μM vs. SAL2-Aoa-GFLG-OT20 with MIC of 141.5 μM). Among all the conjugates the short 
tuftsin derivative containing conjugates (namely SAL2-Aoa-T5, SAL2-Aoa-T5-OH, SAL2-Aoa-TKPR-OH 
and SAL2-Aoa-TKPPR-OH) and their analogues with GFLG spacer showed outstanding in vitro 
antimycobacterial activity against M. tuberculosis H37Rv. The SAL2-Aoa-T5 with amide on the C-terminal 
was three-times more effective than its analogue SAL2-Aoa-T5-OH with C-terminal carboxyl group. The 
most effective conjugates are the SAL2-Aoa-TKPPR-OH (MIC value of 20.3 μM) and SAL2-Aoa-T5 (MIC 
value of 21.8 μM). Their MIC value is only three-times higher than the MIC value of the free salicylanilide 
SAL2. Both conjugates that contain two molecules of SAL2, i.e. SAL2-Aoa-OT20(4-SAL2-Aoa) and 
TKPR-OT10(8-SAL2-Aoa; 13-SAL2-Aoa) were also very effective against M. tuberculosis H37Rv with MIC 
values of 42.2 and 34.8 μM respectively. From the perspective of the length of the fatty acid, butyric acid 
and decanoic acid in SAL2-Aoa-OT20(4-but) (MIC of 63.4 μM) and SAL2-Aoa-OT20(4-dec) (MIC of 76.7 
μM) slightly improved the activity of SAL2-Aoa-OT20 (MIC of 81.5 μM), their analogue without fatty acid. 
In the case of the palmitoylated conjugates, a slight influence of the position of palmitic acid side chain can 
be observed in the activity. SAL2-Aoa-OT20(4-pal) has higher MIC value (92.9 μM) than SAL2-Aoa-OT20, 
on the contrary SAL2-Aoa-OT20(14-pal) has slightly lower MIC value (74.3 μM) than SAL2-Aoa-OT20 
without fatty acid. The presence of the fatty acids has a higher influence on the activity of the shorter 
conjugates. In the case of SAL2-Aoa-T5(4-dec) (MIC of 186.5 μM) and SAL2-Aoa-T5(4-pal) (MIC of 173.1 
μM) the presence of these fatty acids highly reduced their activity compared to their analogue SAL2-Aoa-T5 
without fatty acid (MIC of 21.8 μM). The smallest metabolites produced during lysosomal degradation, 
SAL2-Aoa-Thr-OH and SAL2-Aoa-Gly-OH have a low activity with high MIC values (393.5 and 215.4 μM 
respectively).  
In the aspect of the MIC values calculated to the drug contents of the conjugates, most of the OT20 
conjugates were effective at 25 µg/mL drug content concentration, which is only 10-times higher than the 
MIC of the free SAL1 and SAL2 molecules (2.5 µg/mL). However, among the short tuftsin derivative 
containing conjugates we can find compounds that have even lower MIC values calculated to drug content, 
between 6.8 and 10.6 µg/mL (SAL2-Aoa-T5, SAL2-Aoa-GFLG-T5, SAL2-Aoa-GFLG-TKPR-OH, SAL2-
Aoa-TKPPR-OH and SAL2-Aoa-GFLG-TKPPR-OH).  
The short tuftsin derivative containing conjugates that showed outstanding activity against M. 
tuberculosis H37Rv sensitive strain were selected to be measured on M. tuberculosis A8 MDR strain. These 
conjugates can inhibit the resistant bacteria only at the highest concentration tested, at 100 μg/mL (73.5-
112.4 μM). These MIC values are 2-5-times higher than their MIC values against the sensitive strain. In the 
aspect of the drug content, their average MIC value calculated to the drug content is 31 μg/mL, which is 6-
times higher than the MIC value of the free drug SAL2 (5 μg/mL). 
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Most of the conjugates were active also against M. abscessus. They possessed MIC values between 
40.8 and 224.8 μM. The salicylanilide-OT20 conjugates were the most effective against this strain. The 
SAL1-Aoa-OT20 (MIC= 41.5 μM) and SAL2-Aoa-OT20 (MIC= 40.8 μM) has similar activity as the free 
SAL1 (MIC= 34.5 μM) and SAL2 (MIC= 59.8 μM), and interestingly SAL3-Aoa-OT20 (MIC= 41.2 μM) is 
three-times more effective than the free salicylanilide SAL3 with MIC of 129.4 μM. The other tetratuftsin 
derivative conjugates with spacer, fatty acid side chain or second salicylanilide (SAL2-Aoa-GFLG-OT20, 
SAL2-Aoa-OT20(4-but), SAL2-Aoa-OT20(4-dec), SAL1-Aoa-OT20(4-pal), SAL2-Aoa-OT20(4-pal), 
SAL2-Aoa-OT20(14-pal) and SAL2-Aoa-OT20(4-SAL2-Aoa)) acted similarly with MICs between 70.4 and 
79.3 μM. Having two molecules of salicylanilide in the conjugate showed no significant advantage against 
M. abscessus. The MIC of SAL2-Aoa-OT20(4-SAL2-Aoa) (70.4 μM) is slightly lower than the MIC of 
TKPR-OT10(8-SAL2-Aoa; 13-SAL2-Aoa) (86.9 μM). The dituftsin derivative containing conjugate SAL2-
Aoa-OT10 had fairly good activity (MIC of 56.0 μM). The shortest peptide containing conjugates were the 
least effective with MICs ranged from 146.9-224.8 μM. The incorporation of GFLG spacer made the 
conjugates slightly more active. The presence of fatty acid side chain in the T5 containing conjugates had no 
significant influence on the activity against M. abscessus. According to the MIC values calculated to the 
drug content, the SAL1-3-Aoa-OT20 conjugates (MICdrug content is around 13 μg/mL) were as effective or even 
more effective than the free SAL1-3 molecules (MIC within the range of 10-40 μg/mL). The other OT20 
derivatives with a spacer or fatty acid side chain have MIC values calculated to the drug content around 25 
μg/mL and the average value of the short tuftsin derivative containing conjugates is 60 μg/mL. 
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Table 1. Antimycobacterial activity of the salicylanilides and the salicylanilide-tuftsin conjugates 
compound, conjugate codea 
M. tuberculosis H37Rv M. tuberculosis A8 MDR M. abscessus 
MICb 
 (g/mL) 
MICdrug 
content
c 
(g/mL) 
MIC 
(M) 
MICb 
 (g/mL) 
MICdrug 
content
c 
(g/mL) 
MIC 
(M) 
MICb 
 (g/mL) 
MICdrug 
content
c 
(g/mL) 
MIC 
(M) 
controld 
no 
inhibition 
- - 
no 
inhibition 
- - 
no 
inhibition 
- - 
INHe 0.16 0.16 1.17 1 1 7.3 40 40 291.8 
SAL1 2.5 2.5 8.6 5 5 17.3 10 10 34.5 
SAL2 2.5 2.5 7.5 5 5 15.0 20 20 59.8 
SAL3 8 8 25.9 20 20 64.7 40 40 129.4 
SAL1-Aoa-OT20 200 24.1 83.0 nd nd nd 100 12.0 41.5 
SAL2-Aoa-OT20 200 27.3 81.5 nd nd nd 100 13.6 40.8 
SAL3-Aoa-OT20 200f 25.5 82.4 nd nd nd 100 12.7 41.2 
SAL2-Aoa-GFLG-OT20 400 47.3 141.5 nd nd nd 200 23.6 70.7 
SAL2-Aoa-OT20(4-but) 160 21.2 63.4 nd nd nd 200 26.5 79.3 
SAL2-Aoa-OT20(4-dec) 200f 25.6 76.7 nd nd nd 200 25.6 76.7 
SAL1-Aoa-OT20(4-pal) >250g 27.4 94.5 nd nd nd >200g 21.9 75.6 
SAL2-Aoa-OT20(4-pal) 250 31.0 92.9 nd nd nd >200g 24.8 74.3 
SAL2-Aoa-OT20(14-pal) 200f 24.8 74.3 nd nd nd 200 24.8 74.3 
SAL2-Aoa-OT20(4-SAL2-Aoa) 120 28.2 42.2 nd nd nd 200 47.0 70.4 
SAL2-Aoa-OT10 250 58.4 174.9 nd nd nd 80 18.7 56.0 
TKPR-OT10(8-SAL2-Aoa; 13-SAL2-Aoa) 80 23.2 34.8 nd nd nd 200 58.1 86.9 
SAL2-Aoa-T5 20 7.3 21.8 100 36.4 108.9 160 58.3 174.3 
SAL2-Aoa-GFLG-T5 40 10.3 31.0 100 25.9 77.4 200 51.7 154.8 
SAL2-Aoa-T5(4-dec)-NH2 200
f 62.3 186.5 nd nd nd 200 62.3 186.5 
SAL2-Aoa-T5(4-pal)-NH2 200
f 57.9 173.1 nd nd nd 200 57.9 173.1 
SAL2-Aoa-T5-OH 60 21.8 65.3 100 36.4 108.8 200 72.7 217.7 
SAL2-Aoa-GFLG-T5-OH 60 15.5 46.4 100 25.8 77.3 200 51.7 154.6 
SAL2-Aoa-TKPR-OH 40 15.0 45.0 100 37.6 112.4 200 75.1 224.8 
SAL2-Aoa-GFLG-TKPR-OH 40 10.6 31.6 100 26.4 79.1 200 52.9 158.2 
SAL2-Aoa-TKPPR-OH 20 6.8 20.3 100 33.9 101.3 200 67.7 202.7 
SAL2-Aoa-GFLG-TKPPR-OH 40 9.8 29.4 100 24.6 73.5 200 49.1 146.9 
SAL2-Aoa-Thr-OH 200f 131.5 393.5 nd nd nd nd nd nd 
SAL2-Aoa-Gly-OH 100f 72.0 215.4 nd nd nd nd nd nd 
a The C-terminal of the peptides is in amide form if it is not indicated otherwise, the peptides with carboxylic C-terminal is always indicated with -OH. 
b MIC (minimal inhibitory concentration) was determined on the M. tuberculosis H37Rv, MDR-TB strain A8 (4 weeks) and M. abscessus strain (1 
week) in Sula semisynthetic medium, pH 6.5. To confirm the growth inhibition, CFU (colony forming unit) was determined on Löwenstein-Jensen 
solid media, data are shown in Supporting Information Table S4. 
c Calculated to drug content: MICdrug content (µg/mL) = (MIC (µM) × Mav SAL(g/mol) × n) / 1000, where Mav SAL: molar mass of SAL; n: number of SAL 
in the conjugate. 
d As positive control, bacteria were inoculated in the absence of drugs.  
e
 INH: isoniazid, as a control drug. The MIC values against M. abscessus of the control drugs CIPX and GEN were 40 μg/mL (291.8 μM), 1 μg/mL 
(3.0 μM) and 5 μg/mL (10.5 μM) respectively [9].  
f Data are extrapolated from the data determined after 21 days of incubation. 
g At this concentration the conjugates were able to reduce the CFU, but their MIC value is probably higher than the measured highest concentration. 
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Table 2. In vitro antimycobacterial activity of the previously published parent salicylanilide derivatives [9], 
their cytostatic activity (24 h) on MonoMac6 and HepG2 cells and selectivity indexes calculated for M. 
tuberculosis H37Rv 
 
codea R1 R2 
M. tuberculosis 
H37Rv 
MIC (μM) [9] 
M. tuberculosis 
A8 MDR 
MIC (μM) [9] 
M. abscessus 
MIC (μM) [9] 
MonoMac6 HepG2 
IC50 
(μM) 
SIb for M. 
tuberculosis 
H37Rv 
IC50 
(μM) 
SIb for M. 
tuberculosis 
H37Rv 
2a Cl 4-CF3 1.6 1.6 3.2 2.2±1.2 1.4 5.8±1.9 3.6 
2b Cl 3,4-diCl 1.6 1.6 3.2 3.8±0.5 2.4 2.4±1.0 1.5 
2c Br 4-CF3 1.4 2.8 13.9 2.0±0.4 1.4 5.5±2.1 3.9 
2d Br 3,4-diCl 1.4 2.8 7.0 1.4±0.5 1.0 4.1±1.9 2.9 
a
 Compound codes are identical as in Ref [9]. 
b
 Selectivity index, SI = IC50 (μM)/MIC (μM) 
 
 
2.3. In vitro cytostatic and cytotoxic activity 
Determination of the in vitro cytostatic effect of the compounds was carried out on human monocytic 
cell line MonoMac6 and on human hepatocellular carcinoma cell line HepG2 using MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay after 24 h of incubation. The IC50 values (the 
concentration which decreases the viability of the cells to 50% from the maximal viability) were determined 
from the dose-response curves and are presented in Table 3. The MonoMac6 cells are considered as an in 
vitro model of the host cell macrophages [52]. The HepG2 cells represent the model for the hepatotoxicity.  
The cytotoxic activity of representative compounds was also determined on murine bone marrow-
derived macrophages (BMMΦ) using MTT assay after 48 h of incubation (Supporting Information Table 
S5). BMMΦ cells can be considered also as macrophage model from normal primary cell culture that also 
expresses tuftsin receptors [53]. 
The selectivity indexes (SI) related to M. tuberculosis H37Rv strain were determined as a ratio of the 
IC50 value for cytostatic or cytotoxic activity to the MIC value (Table 2, Table 3 and Table S5). 
Most of the acetylated control peptides have no cytostatic activity on MonoMac6 and HepG2 cells at 
the highest concentration measured (200 μM) (Table 3). Interestingly, among the control peptides with fatty 
acid modification only the derivatives that contain palmitoyl group have cytostatic effect on both cell types. 
Ac-OT20(4-pal) showed the lowest IC50 value on MonoMac6 (26.6 μM). Its isomer with palmitic acid on the 
14
Lys (Ac-OT20(14-pal)) has higher IC50 value (62.8 μM) on MonoMac6. Inversely, the Ac-OT20(14-pal) 
has lower IC50 value (35.2 μM) than Ac-OT20(4-pal) (77.0 μM) on HepG2 cells. In the case of the shorter 
Ac-T5(4-pal) it has similar effect like Ac-OT20(14-pal) on both cells. The cytostatic effect of palmitic acid 
itself and the physical mixture of palmitic acid and Ac-OT20 control peptide was also studied on MonoMac6 
cells, and the IC50 values are very similar (178.1 and 175.8 μM respectively). The covalent bond between the 
palmitic acid and the peptide in the most cytostatic derivative Ac-OT20(4-pal) gives almost 7-times lower 
IC50 value than in the case of the palmitic acid alone.  
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The previously published parent salicylanilides [9] have cytostatic activity at very low IC50 values 
between 1.4-5.8 μM on MonoMac6 and HepG2 cells (Table 2). All the three conjugable salicylanilide 
derivatives (SAL1-3) have cytostatic activity on both cells as well, but their IC50 values are higher than the 
IC50 values of the parent compounds (Table 3). The conjugable salicylanilides (SAL1-3) have very similar 
IC50 values between 16.1-21.5 µM on MonoMac6. SAL1 has the lowest value (7.9 µM) for HepG2 cells, 
SAL2 and SAL3 has IC50 values of 15.9 and 17.6 µM, respectively. 
In the case of the salicylanilide-tuftsin conjugates the results are diverse (Table 3). The conjugates 
with one tuftsin units (SAL2-Aoa-T5, SAL2-Aoa-T5-OH, SAL2-Aoa-TKPR-OH, SAL2-Aoa-TKPPR-OH) 
and their analogues elongated with GFLG spacer have no cytostatic activity on MonoMac6 cells at the 
highest measured concentration (200 µM). Conjugates with two and four tuftsin units without a side chain 
modification (SAL2-Aoa-OT10, SAL1-Aoa-OT20, SAL2-Aoa-OT20, SAL3-Aoa-OT20) also does not show 
cytostatic effects on this cell. The OT20 conjugate elongated with the GFLG spacer (SAL2-Aoa-GFLG-
OT20) has a slight cytostatic activity on MonoMac6 (IC50 of 86.6 µM). The presence of two salicylanilide 
molecules in the conjugate results in the appearance of cytostatic activity, namely SAL2-Aoa-OT20(4-
SAL2-Aoa) with 39.1 µM and TKPR-OT10(8-SAL2-Aoa; 13-SAL2-Aoa) with IC50 of 101.4 µM for 
MonoMac6 cells. The conjugates in which there are fatty acid side chain modification showed a significant 
cytostatic activity on MonoMac6 cells. The conjugate that have the shortest fatty acid side chain 
modification (with butanoyl side chain SAL2-Aoa-OT20(4-but)) has no cytostatic activity as an exception. 
All the palmitoyl side chain containing OT20 conjugates have very low and similar IC50 values (16.5-20.9 
µM) and the T5 analogue (SAL2-Aoa-T5(4-pal)) has higher IC50 value (53.8 µM). The two conjugates that 
have decanoyl side chain modification also have cytostatic activity. The SAL2-Aoa-OT20(4-dec) has IC50 
value of 24.9 µM that is comparable with its analogue that have palmitoyl side chain modification (SAL2-
Aoa-OT20(4-pal), 16.8 µM). The T5 analogue SAL2-Aoa-T5(4-dec) has higher IC50 value (72.6 µM) than 
SAL2-Aoa-T5(4-pal) (53.8 µM). The finding that the decanoyl containing conjugates have cytostatic activity 
is in contrast that we experienced in the case of the control peptides (Ac-OT20(4-dec), Ac-T5(4-dec)) that 
did not show cytostatic activity nor the decanoic acid itself on MonoMac6 cells. 
On HepG2 cells one OT20 conjugate (SAL2-Aoa-OT20) has a slight cytostatic activity (81.9 µM), the 
others (SAL1-Aoa-OT20, SAL3-Aoa-OT20) and the OT10 derivative SAL2-Aoa-OT10 do not exhibited this 
action at the highest concentration measured. The conjugates with one tuftsin unit (SAL2-Aoa-T5, SAL2-
Aoa-TKPR-OH, SAL2-Aoa-TKPPR-OH) do not have cytostatic activity on HepG2 below 200 µM except 
SAL2-Aoa-T5-OH which has a slight cytostatic effect with IC50 value of 191.3 µM. Interestingly, the 
presence of the GFLG spacer (SAL2-Aoa-GFLG-OT20, SAL2-Aoa-GFLG-T5, SAL2-Aoa-GFLG-T5-OH, 
SAL2-Aoa-GFLG-TKPR-OH, SAL2-Aoa-GFLG-TKPPR-OH) makes the conjugates slightly cytostatic on 
HepG2 cells (IC50 values between 58.0-162.2 µM). The conjugates containing two salicylanilide molecules 
have similar IC50 values to SAL2-Aoa-OT20, SAL2-Aoa-OT20(4-SAL2-Aoa) with 79.7 µM and TKPR-
OT10(8-SAL2-Aoa; 13-SAL2-Aoa) with 95.2 µM IC50 value. The conjugates with palmitic acid side chain 
modification showed a significant cytostatic activity on HepG2 cells too. The palmitoyl side chain containing 
OT20 conjugates have low and similar IC50 values (37.6-42.9 µM). Interestingly, the T5 analogue (SAL2-
Aoa-T5(4-pal)) has the lowest IC50 value among all the conjugates (23.2 µM).  SAL2-Aoa-OT20 and its 
analogue with butanoyl side chain (SAL2-Aoa-OT20(4-but)) has the same effect (81.9 and 81.6 µM 
respectively). On the contrary that we can observe in the case of cytostatic activity on MonoMac6 cells, on 
HepG2 cells the cytostatic activity of the OT20 conjugate that has decanoyl side chain modification (SAL2-
Aoa-OT20(4-dec)) is decreased (113.3 µM). The T5 analogue SAL2-Aoa-T5(4-dec) has a higher cytostatic 
activity but its IC50 value (55.8 µM) is still lower than the IC50 value of SAL2-Aoa-T5(4-pal) (23.2 µM).  
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Interestingly, the smallest metabolites from lysosomal degradation SAL2-Aoa-Thr-OH and SAL2-
Aoa-Gly-OH have no cytostatic activity on MonoMac6 cells nor on HepG2 cells at the highest measured 
concentration (200 μM). The presence of the oxime bonded amino acid derivative on the salicylanilide 
abolishes the cytostatic activity. The disappearance of the cytostatic activity is presumably because the 
conjugates and the smallest fragments are not getting into the same cell compartment.  
In the case of the parent salicylanilide derivatives selectivity indexes calculated to M. tuberculosis 
H37Rv ranged from 1.0 to 2.4 for MonoMac6 cells and from 1.5 to 3.9 for HepG2 cells. The conjugable 
derivatives have similar SI values for both cell lines, 0.8-2.5 for MonoMac6 cells and 0.7-2.1 for HepG2 
cells. 
However, most of the conjugates were not cytostatic or possessed low cytostatic activity, their 
selectivity towards M. tuberculosis H37Rv starts at low selectivity indexes due to their higher MIC values. 
The conjugates with decanoic acid or palmitic acid side chain modification have SI values between 0.1 and 
1.5. SAL2-Aoa-OT20(4-SAL2-Aoa) conjugate with two drug molecules has SI value below 1.9 for both 
cells, however, TKPR-OT10(8-SAL2-Aoa; 13-SAL2-Aoa) with also two drug molecules has slightly better 
SI value, 2.9 and 2.7 for MonoMac6 and HepG2 respectively. The conjugates (SAL1-Aoa-OT20, SAL3-
Aoa-OT20, SAL2-Aoa-T5, SAL2-Aoa-T5-OH, SAL2-Aoa-TKPR-OH, SAL2-Aoa-TKPPR-OH) that have 
no cytostatic activity on MonoMac6 or HepG2 cells at the highest measured concentration (200 μM) 
exhibited the most favourable selectivity towards bacteria, their SI values are above 2.4 or even above 9 for 
MonoMac6 and HepG2 cells with SAL2-Aoa-TKPPR-OH superiority. In these cases, we can conclude that 
the conjugation of salicylanilide derivatives to tuftsin type carriers improved their selectivity toward the 
bacteria. 
On BMMΦ cells (murine bone marrow-derived macrophages) the salicylanilide derivative SAL2 itself 
has a moderate cytotoxic effect (76.5 μM) resulted in high selectivity index (10.2) towards bacteria (Table 
S5). Its conjugates with the monotuftsin derivative (SAL2-Aoa-T5) and with the tetratuftsin derivative 
(SAL2-Aoa-OT20) have no cytotoxicity at the highest measured concentration (100 μM). Their selectivity 
indexes are above 4.6 and 1.2, respectively. The incorporation of the GLFG spacer resulted in a low 
cytotoxic activity in the case of SAL2-Aoa-GFLG-OT20 with IC50 value of 92.1 μM. The fatty acid side 
chain modification also increased the cytotoxicity, SAL2-Aoa-OT20(4-dec) has a moderate cytotoxic 
activity (IC50 of 71.9 μM) and SAL2-Aoa-OT20(4-pal) has a high cytotoxic activity (IC50 of 20.4 μM) on 
BMMΦ cells. Therefore, their selectivity indexes are not favourable, SI is below 1. 
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Table 3. Cytostatic activity (24 h) on MonoMac6 and HepG2 cells of SAL1-3, the salicylanilide-tuftsin 
conjugates, the control peptides and selectivity indexes calculated for M. tuberculosis H37Rv 
compound, conjugate codea 
MonoMac6 HepG2 
IC50 (μM) 
SIb for M. 
tuberculosis H37Rv 
IC50 (μM) 
SIb for M. 
tuberculosis H37Rv 
SAL1 16.1±4.9 1.9 7.9±1.4 0.9 
SAL2 18.6±2.5 2.5 15.9±0.0 2.1 
SAL3 21.5±7.1 0.8 17.6±1.6 0.7 
SAL1-Aoa-OT20 >200 >2.4 >200 >2.4 
SAL2-Aoa-OT20 >200 >2.5 81.9±4.2 1.0 
SAL3-Aoa-OT20 >200 >2.4 >200 >2.4 
SAL2-Aoa-GFLG-OT20 86.6±2.8 0.6 112.4±20.0 0.8 
SAL2-Aoa-OT20(4-but) >200 >3.2 81.6±2.4 1.3 
SAL2-Aoa-OT20(4-dec) 24.9±6.2 0.3 113.3±15.3 1.5 
SAL1-Aoa-OT20(4-pal) 16.8±3.1 0.2 42.9±8.9 0.5 
SAL2-Aoa-OT20(4-pal) 16.5±0.8 0.2 37.6±10.3 0.4 
SAL2-Aoa-OT20(14-pal) 20.9±4.0 0.3 40.4±17.7 0.5 
SAL2-Aoa-OT20(4-SAL2-Aoa) 39.1±1.6 0.9 79.7±16.7 1.9 
SAL2-Aoa-OT10 >200 >1.1 >200 >1.1 
TKPR-OT10(8-SAL2-Aoa; 13-SAL2-Aoa) 101.4±5.6 2.9 95.2±4.2 2.7 
SAL2-Aoa-T5 >200 >9.2 >200 >9.2 
SAL2-Aoa-GFLG-T5 >200 >6.5 162.6±17.3 5.3 
SAL2-Aoa-T5(4-dec) 72.6±6.7 0.4 55.8±3.0 0.3 
SAL2-Aoa-T5(4-pal) 53.8±1.1 0.3 23.2±3.7 0.1 
SAL2-Aoa-T5-OH >200 >3.1 191.3±12.4 2.9 
SAL2-Aoa-GFLG-T5-OH >200 >4.3 58.0±0.1 1.3 
SAL2-Aoa-TKPR-OH >200 >4.4 >200 >4.4 
SAL2-Aoa-GFLG-TKPR-OH >200 >6.3 112.6±26.9 3.6 
SAL2-Aoa-TKPPR-OH >200 >9.9 >200 >9.9 
SAL2-Aoa-GFLG-TKPPR-OH >200 >6.8 155.6±14.8 5.3 
SAL2-Aoa-Thr-OH >200 >0.5 >200 >0.5 
SAL2-Aoa-Gly-OH >200 >0.9 >200 >0.9 
most of the acetylated control peptides >200 - >200 - 
Ac-OT20(4-pal) 26.6±2.2 - 77.0±7.1 - 
Ac-OT20(14-pal) 62.8±4.5 - 35.2±5.2 - 
Ac-T5(4-pal) 64.0±0.6 - 43.5±7.9 - 
decanoic acid >200 - ndc - 
palmitic acid 178.1±11.2 - nd - 
palmitic acid + SAL2-Aoa-OT20 physical mixture 169.0±1.7 - nd - 
palmitic acid + Ac-OT20 physical mixture 175.8±14.0 - nd - 
a
 The C-terminal of the peptides is in amide form if it is not indicated otherwise, the peptides with carboxylic 
C-terminal is always indicated with -OH.
 
b
 Selectivity index, SI = IC50 (μM)/MIC (μM) 
c 
nd: not determined. 
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2.4. Study of the pH dependence of the fluorescence intensity of the fluorescently labelled tuftsin 
derivatives 
It is important to know the fluorescent properties of the fluorescently labelled different tuftsin 
derivatives to be able to compare their cellular uptake rates. Therefore prior to the cellular uptake studies the 
pH dependence of the fluorescence intensity of the fluorescently labelled tuftsin derivatives was studied in 
citric acid – Na2HPO4 buffers at 8 and 50 μM concentration using Varian Cary Eclipse Fluorescence 
Spectrophotometer. Preparation of buffers can be found in Supporting Information Table S6. As excitation 
wavelength 488 nm was used and the emission was measured between 490 and 700 nm, 450 V detector 
voltage was used. At the different concentrations similar tendency in the fluorescence intensity was 
observed, data obtained at 50 μM are presented here, data obtained at 8 μM are presented in Supporting 
Information (Figure S8-S9). 
The fluorescence intensity and the emission maximum wavelength of all 5(6)-carboxyfluorescein 
labelled peptides (Cf-tuftsin derivatives) and the free 5(6)-carboxyfluorescein increase along with pH 
between pH 4 and pH 6. Between pH 6 and pH 7.6 no significant differences in the intensity and emission 
maximum wavelength was observed, at these pH values the fluorescence intensity and the emission 
maximum wavelength is the highest. Most of the peptides and the free 5(6)-carboxyfluorescein follow the 
same emission spectra profile. The emission spectra at different pH values of Cf-OT20 and Cf-T5 are 
showed as an example in Figure 2A and B. The emission spectra of all Cf-tuftsins at pH 7 are compared in 
Figure 2C. The sequence, the number of tuftsin units, the presence of the spacer, the presence of butyric or 
decanoic acid has no significant effect on the fluorescent properties of the peptides. However, in the case of 
peptides with palmitic acid at the 4
th
 position (Cf-OT20(4-pal) and Cf-T5(4-pal)) the fluorescence intensity 
dramatically decreased at all pH value. At this distance the palmitic acid can have quenching effect to the 
fluorophore. When the palmitic acid is in the 14
th
 position (Cf-OT20(14-pal)) no decrease in the intensity 
was observed. In the case of the salicylanilide containing fluorescent conjugate SAL2-Aoa-OT20(4-Cf) 
decrease in the florescence intensity also was observed, the salicylanilide also can have quenching effect at 
this distance. 
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Figure 2. Comparison of the pH dependence of the fluorescence intensity of the Cf-labelled tuftsin 
derivatives: (A) Cf-OT20 and (B) Cf-T5. (C) Comparison of the fluorescence intensity of the different Cf-
labelled tuftsin derivatives at pH 7 at 50 μM, in 0.1 M citric acid – 0.2 M Na2HPO4 buffer. The arrows 
indicate the compounds with lower fluorescence intensity than the average. 
 
2.5. Cellular uptake experiments of fluorescently labelled tuftsin derivatives 
The in vitro cellular uptake of the different fluorescently labelled tuftsin derivatives was evaluated on 
MonoMac6 human monocytic cell culture using flow cytometry (BD LSRII) and fluorescent microscopy 
(Olympus CKX41). The cells were treated with the compounds for 3 h, after washing and trypsinization, the 
cells were transferred into tubes and their intracellular fluorescence intensity was measured that is related 
with the cellular uptake rate.  
The uptake of all tuftsin derivatives is concentration dependent in MonoMac6 cells. The concentration 
dependency of the uptake of representative Cf-labelled tuftsin derivatives is presented in Supporting 
Information Figure S10. In Figure 3A the mean intracellular fluorescence intensity of the living Cf positive 
cells treated with the compounds at the highest measured concentration (200 μM) is compared. The uptake 
depends on the number of the tuftsin unites: the internalization of the longer peptides is higher than 
internalization of the shorter ones (Cf-OT20 > Cf-OT10 > Cf-T5). The uptake of the peptides with one 
tuftsin unite (Cf-T5, Cf-T5-OH, Cf-TKPR-OH and Cf-TKPPR-OH) is very similar, the form of the C-
terminal does not have significant effect (amide or free carboxyl form, Cf-T5 vs. Cf-T5-OH). The presence 
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of the GFLG spacer slightly reduced the internalization. The small differences in the lipophilicity of the 
peptides seem to have no effect on the uptake. 
The OT20 derivatives with palmitic acid side chain (Cf-OT20(4-pal) and Cf-OT20(14-pal)) showed an 
extremely high uptake rate. At the applied experimental condition they have approximately 36-times higher 
uptake rate than their analogue without palmitic acid (Cf-OT20). The position of the palmitic acid in the 
sequence has no influence on the intracellular fluorescence intensity. The smaller peptide with palmitic acid 
(Cf-T5(4-pal)) has approximately four-times smaller uptake rate than the longer ones (Cf-OT20(4-pal) and 
Cf-OT20(14-pal)) but this rate is still more higher than the peptides without palmitic acid. Cf-T5(4-pal) has 
20-times higher uptake rate than Cf-T5 without fatty acid. Unfortunately, these compounds showed a 
cytotoxic activity after 3 h treatment at this concentration of 200 μM. Table 4 shows the 3 h IC50 values of 
the Cf-peptides calculated from the percentage of the living cells determined by the flow cytometer 
according to the size and granularity of the cells. In the case of the peptides with decanoic acid side chain 
modification the longer Cf-OT20(4-dec) has a significantly higher internalization rate among the peptides; it 
has 8-times higher uptake rate than Cf-OT20 and almost 10-times higher uptake rate than the smaller Cf-
T5(4-dec). It should also be noted that Cf-T5(4-dec) has two-times higher uptake rate than its analogue 
without decanoic acid (Cf-T5). The uptake rate of Cf-OT20(4-pal) is almost 5-times higher than its analogue 
with decanoic acid (Cf-OT20(4-dec)). The advantage of using decanoic acid modification instead of palmitic 
acid is that the derivatives with decanoic acid have no cytotoxic activity after 3 h treatment. Introduction of 
butyric acid side chain has no significant effect (Cf-OT20 vs. Cf-OT20(4-but)). The increasing cellular 
uptake of peptides with decanoic or palmitic acid side chain can be the result of their higher lipophilic 
characters (according to retention time data from TableS1) than their analogues without these fatty acid side 
chains.  
Interestingly, the fluorescently labelled OT20 derivative that has salicylanilide moiety conjugated to it 
(SAL2-Aoa-OT20(4-Cf)) has almost two-times higher uptake rate than the Cf-OT20 without salicylanilide 
moiety. Again this finding can be explained by the increased lipophilicity in the case of SAL2-Aoa-OT20(4-
Cf). 
Figure 3B shows the mean fluorescence intensity values of the living cells treated with 8 μM and 40 
μM solutions of the selected peptides. The palmitic acid containing peptides does not have cytotoxic activity 
at the concentration of 8 μM, the rate of the living cells is above 80%, in the case of the untreated control 
cells this is 95%. At this concentration the intracellular fluorescence intensity of the cells treated with 
derivatives with decanoic acid (Cf-OT20(4-dec) and Cf-T5(4-dec)) and their analogue without fatty acid side 
chain (Cf-OT20 and Cf-T5) is only slightly higher than the fluorescence of the untreated control cells. 
However, the uptake rate of the derivatives with palmitic acid side chain modification (Cf-OT20(4-pal), Cf-
OT20(14-pal), Cf-T5(4-pal)) is still very significant at the concentration of 8 µM.  
The cellular uptake of selected fluorescently labelled tuftsin derivatives was visualized using 
fluorescent microscopy (Figure 4). The morphology of the cells treated with most of the Cf-peptides is 
normal, similar to control cells. The morphology of the cells treated with Cf-peptides that contain palmitic 
acid side chain moiety is different when the cells were treated with 200 μM and 40 μM of the peptide, at 8 
μM the cell morphology remains normal. Figure 4F-H shows the microscopic images of the MonoMac6 cells 
treated with Cf-OT20(4-pal) at different concentrations as an example. 
The comparison of the mean intracellular fluorescence intensity values of the cells treated with the 
different peptides is adequate in the case of most of the peptides that have similar fluorescent properties. In 
the case of Cf-OT20(4-pal), Cf-T5(4-pal) and SAL2-Aoa-OT20(4-Cf), where the peptides have lower 
fluorescent intensity under the same circumstances probably because of self-quenching, higher cellular 
 22 
 
uptake rate was measured than in the case of the other peptides. This fact implies that the peptide is degraded 
in the cells and the self-quenching is eliminated.  The position of the palmitic acid in the peptide sequence 
has no influence to the cellular uptake rate, no significant difference between the intracellular fluorescence 
intensity was observed in the case of Cf-OT20(4-pal) and Cf-OT20(14-pal). However, in buffers at the 
measured pH values the fluorescence intensity of Cf-OT20(14-pal) is much higher than the fluorescence 
intensity of Cf-OT20(4-pal). This finding suggests that the Cf-OT20(4-pal) and the Cf-OT20(14-pal) must be 
degraded in the cell therefore the self-quenching is abolished resulting the same intracellular fluorescence 
intensity. 
 
 
Figure 3. (A) Comparison of the cellular uptake on MonMac6 cells of the different fluorescently labelled 
tuftsin derivatives using flow cytometry at 200 μM compound concentration (3 h incubation time). (B) 
Comparison of the cellular uptake of selected fluorescently labelled tuftsin derivatives at 8 μM and 40 μM 
compound concentrations (3 h incubation time). 
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Table 4. Cytotoxic activity (3 h) of the fluorescently labelled peptides on MonoMac6 cells determined by the 
data from the measurement with flow cytometer 
compound, conjugate codea 
MonoMac6 
IC50 (M) 
most of the Cf-labelled peptides >200 
Cf-OT20(4-pal) 13.3 
Cf-OT20(14-pal) 14.3 
Cf-T5(4-pal) 109.2 
a
 The C-terminal of the palmitoylated peptides is in amide form. 
 
   
   
   
   
Figure 4. Comparison of the cellular uptake (3 h) of selected fluorescently labelled tuftsin derivatives on 
MonoMac6 cells using fluorescent microscopy, bright field microscopic images and fluorescent microscopic 
images are shown. (A) Untreated control cells, (B) Cf-OT20, 200 μM, (C) SAL2-Aoa-OT20(4-Cf), 200 μM, 
(D) Cf-T5, 200 μM, (E) Cf-OT20(4-dec), 200 μM, (F) Cf-OT20(4-pal), 200 μM, (G) Cf-OT20(4-pal), 40 
μM, (H) Cf-OT20(4-pal), 8 μM. 
 
The cellular uptake of the selected fluorescently labelled tuftsin derivatives (Cf-OT20, Cf-GFLG-
OT20, Cf-OT20(4-dec), Cf-OT20(4-pal), Cf-OT10, Cf-T5, Cf-TKPR-OH, Cf-TKPPR-OH) was also 
evaluated on murine bone marrow-derived macrophages (BMMΦ, macrophage model from normal primary 
cell culture with tuftsin receptors [53]) using flow cytometry and fluorescent microscopy. The cells were 
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treated with the compounds for 3 h, after washing and trypsinization, the cells were transferred into tubes and 
their intracellular fluorescence intensity was measured.  
The uptake of the selected Cf-tuftsin derivatives by BMMΦ cells showed similar tendency as by 
MonoMac6 cells (Supporting Information Figure S11). The uptake rate of the longer peptides is higher than 
the shorter peptides, but with slighter difference (Cf-OT20>Cf-OT10>Cf-T5). No significant difference can 
be observed between the intracellular fluorescence intensity of Cf-OT20 and its analogue elongated with the 
GFLG spacer, Cf-GFLG-OT20. The uptake rate of the small Cf-TKPR-OH and Cf-TKPPR-OH is higher 
than the rate of the Cf-T5, their intracellular fluorescent intensity is similar to the intensity of Cf-OT20 
tetratuftsin derivative. The uptake rate of Cf-OT20(4-dec) and Cf-OT20(4-pal) decanoylated and 
palmitoylated tetratuftsin derivatives are outstanding, similarly as in the case of the MonoMac6 cells. 
 
 
2.6. Membrane integrity studies by propidium iodide staining 
Propidium iodide (PI) is used to distinguish the dead or nonviable cells from living cells, as PI only 
stains cells with irreparably damaged membranes that can be described as nonviable or dead [54]. Therefore, 
PI staining was used to compare the effect of the control acetylated tuftsin derivatives with or without fatty 
acid side chains (Ac-OT20, Ac-OT20(4-dec), Ac-OT20(4-pal) and Ac-OT20(14-pal)) to the cell membrane 
integrity using flow cytometry and fluorescent microscopy. MonoMac6 cells were treated with the peptide 
derivatives for 3 h, at different concentrations (8, 40 and 200 μM), after washing and trypsinization, the cells 
were transferred into tubes and solution of PI was added to it. The intracellular fluorescence intensity was 
measured before and after adding the PI solution. 
In Figure 5 the microscopic image shows the MonoMac6 cells with PI after treatment with the 
compounds for 3 h at 200 μM. The Ac-OT20 with no fatty acid side chain and the Ac-OT20(4-dec) with 
decanoyl side chain have no influence on the membrane integrity. The presence of PI can be observed only 
in the cells that were treated with palmitoylated tuftsin derivatives (Ac-OT20(4-pal) and Ac-OT20(14-pal)), 
these cells have altered cell morphology and presumably changed cell viability. These palmitoylated peptides 
have the same effect at 40 µM concentration (data not shown), but at 8 µM the rate of the membrane 
damaged cells is decreased. The percentage of the nonviable cells and the percentage of the nonviable and PI 
containing cells are shown in Supporting Information Figure S12. These results are consistent with the 
microscopic images. 
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Figure 5. Membrane integrity studies with propidium iodide (PI) staining of MonoMac6 cells after treatment 
(3 h, 200 μM) with acetylated tuftsin derivatives with different fatty acid side chain modification using 
fluorescent microscopy, bright field microscopic images and fluorescent microscopic images are shown. (A) 
Untreated control cells, (B) Ac-OT20, (C) Ac-OT20(4-dec), (D) Ac-OT20(4-pal), (E) Ac-OT20(14-pal). 
 
2.7. Degradation study of SAL2-tuftsin conjugates in rat liver lysosomal homogenate 
The efficacy of the conjugates is related to their degradation and the intracellular drug release from the 
conjugates in the target cells therefore we studied the stability/degradation of the conjugates in rat liver 
lysosomal homogenate by liquid chromatography in combination with mass spectrometry (HPLC-MS). 
Lysosomes, intracellular organelles that have an internal acidic pH (pH 4.5-5.0) [55] and contain a wide 
variety of hydrolytic enzymes, play a crucial role in the intracellular drug release. 
Analyses (LC-MS chromatogram, mass spectra) of the reaction mixtures of SAL2-Aoa-OT20, SAL2-
Aoa-GFLG-OT20, SAL2-Aoa-OT20(4-dec), SAL2-Aoa-OT20(4-pal), SAL2-Aoa-OT20(14-pal), SAL2-
Aoa-OT20(4-SAL2-Aoa), SAL2-Aoa-OT10, SAL2-Aoa-T5, SAL2-Aoa-GFLG-T5, SAL2-Aoa-T5(4-dec), 
SAL2-Aoa-T5(4-pal), SAL2-Aoa-T5-OH, SAL2-Aoa-TKPR-OH, SAL2-Aoa-TKPPR-OH after 5 min, 1 h, 2 
h, 4 h, 8 h and 24 h are presented in the Supporting Information Figure S13-S27. The smallest drug 
containing metabolite was the SAL2-Aoa-Thr-OH from conjugates without spacer and SAL2-Aoa-Gly-OH 
from conjugates with spacer. SAL2-Aoa-OT20(4-SAL2-Aoa) conjugate released SAL2-Aoa-Thr-OH and H-
Lys(SAL2-Aoa)-OH according to its structure. No cleavage of the oxime bond and no free salicylanilide was 
observed. Figure 6 summarizes the detected cleavage sites during the digestion of the conjugates. 
In the case of most of the TKPKG derivatives without spacer (SAL2-Aoa-OT20, SAL2-Aoa-OT20(4-
dec), SAL2-Aoa-OT20(4-pal), SAL2-Aoa-OT20(14-pal), SAL2-Aoa-OT20(4-SAL2-Aoa), SAL2-Aoa-
OT10, SAL2-Aoa-T5, SAL2-Aoa-T5(4-dec), SAL2-Aoa-T5-OH) the first cleavage sites were observed after 
5 min next to the Gly residues (-Lys-Gly- bond and -Gly-Thr- bond). After 1 h the degradation continued, in 
the case of the OT20 derivatives only a small amount of the intact conjugate was observed, and after 2 h 
there were no intact conjugate in the samples with the exception of the SAL2-Aoa-OT20(4-pal) conjugate. 
The degradation of SAL2-Aoa-OT20(4-pal) was slow, several cleavage sites were observed. The intact 
A B 
E 
50 µm 
D C 
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SAL2-Aoa-OT20(4-pal) was detected in a very small amount even after 24 h of incubation. The palmitic 
acid in the position 4 slows down the degradation of the conjugate, however, the palmitic acid in the position 
14 has no significant influence on the degradation rate. In the case of the two drug molecule containing 
conjugate SAL2-Aoa-OT20(4-SAL2-Aoa) the H-Lys(SAL2-Aoa)-OH fragment was released sooner with the 
cleavage of -
3
Pro-
4
Lys(SAL2-Aoa)- and -
4
Lys(SAL2-Aoa)-
5
Gly- bonds than the SAL2-Aoa-Thr-OH 
fragment from the N-terminal of the conjugate. 
The degradation of SAL2-Aoa-OT10 is slower than the degradation of SAL2-Aoa-OT20, intact 
SAL2-Aoa-OT10 conjugate is present after 24 h and the SAL2-Aoa-T5-OH fragment is the most intensive 
after 24 h. In the case of the SAL2-Aoa-T5 and SAL2-Aoa-T5-OH the degradation pattern is the same with a 
very slow degradation rate, after 24 h the most intensive component is the intact conjugate in both case. The 
degradation rate of SAL2-Aoa-T5(4-pal) is very low, similar to its analogue without the palmitic acid side 
chain modification (SAL2-Aoa-T5). The presence of the decanoic acid caused the most noticeable difference 
in the digestion of the T5 derivatives. Contrary to the SAL2-Aoa-T5 and SAL2-Aoa-T5(4-pal), the SAL2-
Aoa-T5(4-dec) conjugate was completely degraded after 2 h. In the case of SAL2-Aoa-OT20(4-dec) and 
SAL2-Aoa-T5(4-dec) cleavage of -
3
Pro-
4
Lys(dec)- bond occurred already after 5 min. The decanoic acid 
containing conjugates are digested faster than the other analogues, so the presence of decanoic acid speeds 
up the degradation process. Palmitic acid loss (hydrolysis of the amide bond between the ε-amino group of 
Lys and carboxyl group of palmitic acid) occurred in all the palmitic acid containing conjugates, however, 
decanoic acid loss was not observed. In the case of SAL2-Aoa-TKPR-OH conjugate after 5 min the first 
cleavage sites appeared between -
3
Pro-
4
Arg- and -
2
Lys-
3
Pro- bond. After 24 h a small amount of the intact 
conjugate was still present, the main fragments were SAL2-Aoa-TK-OH and SAL2-Aoa-Thr-OH. In the case 
of its analogue with an extra proline SAL2-Aoa-TKPPR-OH conjugate, the first cleavage site after 5 min is 
the cleavage of the -
4
Pro-
5
Arg- bond. The resulting SAL2-Aoa-TKPP-OH showed a high stability towards 
the lysosomal enzymes, this is the main fragment after 24 h, and only a small part of this fragment could be 
degraded further to smaller metabolites. According to the analysis of the GFLG spacer containing conjugates 
the spacer sequence was primarily hydrolysed in the presence of lysosomal enzymes, the cleavage of -
1
Gly-
2
Phe-, -
2
Phe-
3
Leu- and -
3
Leu-
4
Gly- bond was detected after 5 min. There is no intact conjugate after 2 h, 
small amount of SAL2-Aoa-GF-OH is observed between 5 min and 8 h, but after 24 h only the smallest 
fragment, SAL2-Aoa-Gly-OH is detected. The insertion of enzyme labile GFLG spacer led to an increased 
degradation rate as expected [56]. 
 27 
 
   
 
Figure 6. The detected cleavage sites during the degradation of SAL2-tuftsin conjugates in rat liver 
lysosomal homogenate. 
 
2.8. Intracellular antimycobacterial activity 
In vitro antimycobacterial activity of the compounds on extracellular M. tuberculosis H37Rv culture is 
important, but it is crucial that the compound is efficient against intracellular bacteria, too. Intracellular 
efficacy of salicylanilide-tuftsin conjugates was evaluated on infected MonoMac6 human monocytes. 
MonoMac6 was established as a cell line which appears to have phenotypic and functional characteristic of 
mature blood monocytes [52, 57, 58]. MonoMac6 cells are attached to the tissue culture plate’s well surface 
without any treatment after hours as a homogeneous cell population. Therefore infected MonoMac6 cell line 
is frequently used as a host cell model to determine intracellular activity of antituberculars against 
phagocytosed intracellular bacteria [38, 42]. Monolayer of MonoMac6 was infected with M. tuberculosis 
H37Rv. The infected cells were than treated with the free drugs and the conjugates using concentrations of 
125 μM and 250 μM. After 3 days the treatment was repeated with fresh solution of the compounds for an 
additional 3 days. Untreated infected cells were considered as negative control. The results are summarized 
in Figure 7. 
INH was also tested and did not show antitubercular activity against intracellular bacteria even at 365 
μM concentration [38]. The free salicylanilide derivatives did not exhibit intracellular antitubercular activity 
at none of the used concentrations. In contrast, most of the conjugates significantly reduced the colony 
forming units (CFU) of intracellular M. tuberculosis bacteria compared to untreated control in a 
concentration dependent manner. Among the OT20 conjugates SAL1-Aoa-OT20 was more effective than 
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SAL2-Aoa-OT20 and SAL3-Aoa-OT20 at both concentrations. However, in the case of SAL1-Aoa-OT20(4-
pal) and SAL2-Aoa-OT20(4-pal) the activity was very similar. In terms of the length of the tuftsin 
derivatives at 125 μM there is no significant difference, at 250 μM the smallest SAL2-Aoa-T5 was the most 
effective followed by the longest SAL2-Aoa-OT20. SAL2-Aoa-OT10 resulted in approximately 5-times 
higher CFU than SAL2-Aoa-T5. The presence of the GFLG spacer in the case of most peptide has no 
influence on the activity, only in the case of SAL2-Aoa-TKPR-OH, the presence of the spacer reduced its 
activity 25-times (SAL2-Aoa-GFLG-TKPR-OH). At 250 μM the SAL2-Aoa-T5 with amide on the C-
terminal was 10-times more effective than its analogue SAL2-Aoa-T5-OH with carboxyl group on the C-
terminal of the peptide. The same tendency can be observed in the case of the derivatives of these peptides 
with GFLG spacer (SAL2-Aoa-GFLG-T5 vs. SAL2-Aoa-GFLG-T5-OH). The OT20 derivative which 
contains two molecules of salicylanilides, SAL2-Aoa-OT20(4-SAL2-Aoa) showed a weaker activity than its 
analogue with only one drug molecule SAL2-Aoa-OT20. The conjugate TKPR-OT10(8-SAL2-Aoa; 13-
SAL2-Aoa) that contains also two salicylanilides has better activity than SAL2-Aoa-OT20(4-SAL2-Aoa). It 
was also more effective than SAL2-Aoa-OT20 and SAL2-Aoa-OT10 at 250 µM concentration, but less 
effective than SAL2-Aoa-TKPR. SAL2-Aoa-OT20(4-but) has slightly better activity than SAL2-Aoa-OT20 
conjugate without fatty acid side chain.  The decanoic or palmitic acid side chain containing OT20 derivative 
(SAL2-Aoa-OT20(4-dec), SAL1-Aoa-OT20(4-pal), SAL2-Aoa-OT20(4-pal) and SAL2-Aoa-OT20(14-pal)) 
were outstandingly effective both at 125 and 250 µM concentration. At 250 µM SAL2-Aoa-OT20(4-pal) 
resulted in 5-times lower CFU value than its analogue where the palmitic acid is on the 14
th
 amino acid 
residue SAL2-Aoa-OT20(14-pal). In the case of the T5 derivatives both fatty acid containing conjugates 
SAL2-Aoa-T5(4-dec) and SAL2-Aoa-T5(4-pal) showed a better activity than SAL2-Aoa-T5 without fatty 
acid side chain. Interestingly at 125 µM the decanoic acid containing derivative proved to be better than the 
palmitic acid containing one, but this result is reversed at 250 µM. The OT20 derivatives containing the fatty 
acids (SAL2-Aoa-OT20(4-dec) and SAL2-Aoa-OT20(4-pal)) showed a more improved effect in comparison 
with T5 derivatives SAL2-Aoa-T5(4-dec) and SAL2-Aoa-T5(4-pal). The smallest metabolites produced 
during lysosomal degradation, SAL2-Aoa-Thr-OH and SAL2-Aoa-Gly-OH, also showed an activity against 
the intracellular bacteria without dependence of concentration. They can reduce the CFU values similarly as 
e.g. conjugate SAL2-Aoa-OT10, SAL2-Aoa-TKPPR-OH or SAL2-Aoa-GFLG-TKPPR-OH (at 250 μM). 
Taken together the results of the ability to inhibit intracellular bacteria and cytostatic activity of the 
compounds on the host cell MonoMac6, we can conclude that the conjugates showing cytostatic activity with 
IC50 value lower than 125 μM can be cytostatic on MonoMac6 cells at the applied concentrations (125 μM 
and 250 μM). At the washing steps the dead cells with bacteria might be washed out, therefore decrease of 
CFU can be observed. However, the free salicylanilides also have cytostatic activity at these concentrations 
but the treatment with the free drug molecules did not reduce the CFU at all, the bacteria survive. Therefore, 
the activity of the conjugates against the intracellular bacteria cannot be attributed to their cytostatic activity 
to the host cells. They reduce the CFU probably because of their better intracellular availability. This could 
be due to the better cellular uptake rate of conjugates than the free drugs into the host cells. 
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Figure 7. The in vitro activity of the free salicylanilides and their peptide conjugates on M. tuberculosis 
H37Rv infected host cell model MonoMac6 cells. *(TKPR-OT10(SAL2)2 = TKPR-OT10(8-SAL2-Aoa; 13-
SAL2-Aoa)) 
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3. Conclusions 
The major goal of our work was to synthesize, chemically and biologically characterize salicylanilide-
tuftsin conjugates that have in vitro antimycobacterial activity especially against intracellular bacteria and 
increased cellular uptake rate on the host cell model.  
The salicylanilide derivatives have outstanding in vitro antimycobacterial effect on the extracellular 
bacteria but their activity is overshadowed by their cytostatic activity against the host cell monocytes and 
against the hepatocytes. In the case of the salicylanilide-tuftsin conjugates this antimycobacterial activity is 
mostly preserved with the conjugation to peptides by oxime bond (Figure 8). Moreover there are conjugates 
that have MIC values only slightly higher than the MIC value of the free salicylanilide and these conjugates 
showed no cytostatic activity on the host cells, therefore the selectivity of the salicylanilide was enhanced 
successfully towards the bacteria. The common characteristic of these conjugates that they contain only one 
tuftsin unit with or without the presence of spacer (SAL2-Aoa-T5, SAL2-Aoa-GFLG-T5, SAL2-Aoa-T5-
OH, SAL2-Aoa-GFLG-T5-OH, SAL2-Aoa-TKPR-OH, SAL2-Aoa-GFLG-TKPR-OH, SAL2-Aoa-TKPPR-
OH, and SAL2-Aoa-GFLG-TKPPR-OH).  
 
 
Figure 8. Sorting of the salicylanilide-tuftsin conjugates according to their inhibition ability on the 
extracellular bacteria and their cytostatic effect on MonoMac6 cells. 
 
More importantly, all the conjugates decreased the enumerated colonies of the intracellular bacteria 
after cell lysis while the free salicylanilides were inactive. The improved intracellular efficacy of the 
conjugates on infected cells can be explained probably with the better internalization of the conjugated 
antitubercular drugs than the free drugs (Figure 9). We can estimate the internalization rate of the conjugates 
from the result of the cellular uptake study of the fluorescently labelled carriers. The inhibition effect against 
the intracellular bacteria is increasing with the estimated intracellular uptake rate in the case of most of the 
conjugates. Unfortunately, the conjugates that could have the highest cellular uptake rate and the highest 
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activity against intracellular bacteria, possessed high or medium cytostatic activity. Their common property 
is that they have decanoic or palmitic acid side chain modification (SAL2-Aoa-OT20(4-dec), SAL2-Aoa-
OT20(4-pal), SAL2-Aoa-OT20(14-pal), SAL2-Aoa-T5(4-dec), and SAL2-Aoa-T5(4-pal)). However, the 
decanoic acid containing monotuftsin conjugate, SAL2-Aoa-T5(4-dec) with moderate cytostatic activity and 
outstanding activity against intracellular bacteria is a favourable candidate for further investigation. Most of 
the non-cytostatic conjugates that have significant efficacy against the extracellular bacteria were also 
effective against the intracellular bacteria. The most promising ones among these conjugates are the SAL2-
Aoa-T5, SAL2-Aoa-GFLG-T5 and SAL2-Aoa-TKPR-OH monotuftsin derivatives. 
 
 
Figure 9. Map of the in vitro activity of the salicylanilide-tuftsin conjugates: correlation between the 
estimated internalization rate on MonoMac6 cells and the inhibition of intracellular bacteria. The efficacy on 
the extracellular bacteria and the cytostatic effect on MonoMac6 cells are also indicated. 
 
As an indirect approach we have estimated the lipophilic-hydrophilic character of the conjugates using 
retention time obtained by high performance liquid chromatography. Our reference compounds were injected 
onto a C18 column. The retention time of compounds with known logP values were used to predict the 
lipophilic character of the tuftsin conjugate. In the aspect of the in vitro antimycobacterial activity on 
intracellular bacteria and lipophilicity of the salicylanilides and conjugates there is no obvious correlation 
(Figure S28). The free salicylanilide derivatives with high lipophilicity were not effective against the 
intracellular bacteria. However, we can conclude that having increased lipophilic properties by decanoic or 
palmitic acid side chain modification outstandingly enhanced the cellular uptake rate of the carrier peptides 
along with the activity against the intracellular bacteria. Moreover, the most lipophilic conjugate, the 
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palmitic acid side chain containing monotuftsin derivative (SAL2-Aoa-T5(4-pal)) was one of the most 
efficient in the aspect of the inhibition of the intracellular bacteria. Although, conjugates without fatty acid 
side chains therefore considered rather hydrophilic compounds also were able to significantly inhibit the 
intracellular bacteria without being cytostatic to the host cell model. 
The conjugates regardless to their mostly hydrophilic characters probably have enhanced cellular 
uptake that can occur by receptor mediated endocytosis or phagocytosis. Increasing the lipophilicity can 
result enhanced non-specific transport (diffusion) through the cell membrane. 
In the lysosomal homogenate the conjugates with the GFLG spacer have the highest degradation rate, 
they provide the smallest metabolite the soonest. The presence of the decanoic acid side chain modification 
increased, while the presence of the palmitic acid side chain modification decreased the degradation rate of 
the conjugates, and usually the stability of the shorter peptides are higher than the stability of the longer 
ones.  However, the differences in the stability of the conjugates in lysosomal homogenate were not related 
with the intracellular activity, our intracellular model is not sensitive enough to see the effect of the different 
degradation pattern of the conjugates. 
In summary we can conclude that the antimycobacterial activity of the salicylanilide derivatives is 
preserved in the conjugates; the minimal inhibitory concentration of the conjugates was similar to the free 
drugs or higher. Improved selectivity towards the bacteria was achieved with the conjugation of 
salicylanilides in most of the cases. It is highly important that the salicylanilide-peptide conjugates were 
effective against the intracellular bacteria in contrast with the free drugs, probably due to the better 
internalization rate of the conjugates than the free drugs. 
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4. Experimental Section 
 
4.1. Chemistry 
 
4.1.1. General Methods 
All reagents and solvents were purchased from Sigma-Aldrich and Merck. Commercial grade reagents 
were used without a further purification. Reactions were monitored by thin layer chromatography plates 
coated with 0.2 mm silica gel 60 F254 (Merck), which were visualized by UV irradiation (254 nm). All 
melting points were determined on a Melting Point machine B-540 (Büchi) apparatus using open capillaries 
and they are uncorrected. Infrared spectra (KBr pellets) were recorded on FT-IR spectrometer Nicolet 6700 
FT-IR (Thermo Fisher Scientific, Waltham, MA, USA) in the range of 400-4000 cm
-1
 using the ATR 
technique. The NMR spectra were measured at ambient temperature on a Varian VNMR S500 instrument 
(500 MHz for 
1
H and 126 MHz for 
13
C; Varian Comp. Palo Alto, CA, USA) using deuterated dimethyl 
sulfoxide (DMSO-d6) solutions of the samples. The chemical shifts, δ, are given in ppm, related to 
tetramethylsilane as an internal standard. The coupling constants (J) are reported in Hz. Elemental analysis 
(C, H, N) was performed on an automatic microanalyser CHNS-O CE instrument (FISONS EA 1110, 
Milano, Italy). Measured monoisotopic or average molecular mass was acquired by Bruker Esquire 3000+ 
ESI-MS. Samples were dissolved in a mixture of acetonitrile/water = 1/1 (v/v) containing 0.1% acetic acid 
and introduced by a syringe pump with a flow rate of 10 μL/min.  
 
4.1.1.1. Synthesis of the salicylanilide derivatives 
Salicylanilides were prepared by the reaction of the appropriate substituted salicylic acids (5 mmol) 
and the substituted anilines (5 mmol) in the presence of phosphorus trichloride (2.5 mmol) in chlorobenzene 
[46]. The reaction was carried out with vigorously stirring in a microwave reactor (MicroSYNTH MLS 
ETHOS 1600 URM) for 22 min to reflux. The reaction mixture was filtered while hot, let stand at 20 °C and 
then at 4 °C for 24 h. The crude product was filtered off and he mother liquor was partly evaporated to the 
crystallization to obtain the second portion of crude product. The crude product was suspended in 5 % 
sodium bicarbonate water solution and stirred until cessation of CO2 was observed. The crystals were filtered 
off and then suspended in 0.1 M HCl. The mixture was filtered off, washed with distilled water and the 
obtained pure product was dried. 
 
N-(4-Acetylphenyl)-5-chloro-2-hydroxybenzamide (SAL1) 
Yellowish solid; yield: 7 %; mp: 231-233 °C. IR (ATR): 3322, 1677, 1642, 1591, 1538, 1483, 1415, 1357, 
1324, 1277, 1222, 1181, 1137, 1104, 967, 907, 843, 825, 700, 670, 652. 
1
H NMR (500 MHz, DMSO): δ 
11.64 (1H, bs, OH), 10.62 (1H, bs, NH), 7.97 (2H, d, J = 8.6 Hz, H3´, H5´), 7.89 (1H, d, J = 2.7 Hz, H6), 
7.86 (2H, d, J = 8.7 Hz, H2´, H6´), 7.46 (1H, dd, J = 8.8 Hz, J = 2.7 Hz, H4), 7.03 (1H, d, J = 8.8 Hz, H3), 
2.55 (3H, s, CH3). 
13
C NMR (126 MHz, DMSO): δ 196.75, 165.09, 156.46, 142.71, 133.23, 132.60, 129.55, 
129.36, 128.85, 123.01, 119.93, 119.19, 26.67. Mwmonoizotopic (calc/meas): 289.1 / 289.1. Anal. Calcd. for 
C15H12ClNO3 (289.71): C, 62.19; H, 4.18; N, 4.83; Found: C, 62.02; H, 4.19; N, 4.74. 
 
N-(4-Acetylphenyl)-5-bromo-2-hydroxybenzamide (SAL2) 
Yellowish solid; yield: 6 %; mp: 243-245°C. IR (ATR): 3335, 1671, 1637, 1530, 1482, 1414, 1359, 1332, 
1270, 1221, 1182, 1140, 1096, 962, 909, 820, 778, 658. 
1
H NMR (500 MHz, DMSO): δ 11.64 (1H, bs, OH), 
10.62 (1H, bs, NH), 8.01 (1H, d, J = 2.5 Hz, H6), 7.97 (2H, d, J = 8.6 Hz, H3´, H5´), 7.85 (2H, d, J = 8.6 Hz, 
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H2´, H6´), 7.57 (1H, dd, J = 8.8 Hz, J = 2.6 Hz, H4), 6.97 (1H, d, J = 8.8 Hz, H3), 2.55 (3H, s, CH3). 
13
C 
NMR (126 MHz, DMSO): δ 196.75, 165.02, 156.86, 142.70, 136.03, 132.59, 131.69, 129.54, 121.02, 
119.92, 119.60, 110.41, 26.67. Mwmonoizotopic (calc/meas): 333.0 / 333.1. Anal. Calcd. for C15H12BrNO3 
(334.16): C, 53.91; H, 3.62; N, 4.19;  Found: C, 54.01; H, 3.59; N, 4.22. 
 
5-Formyl-2-hydroxy-N-[4-(trifluoromethyl)phenyl]benzamide (SAL3) 
Yellowish solid; yield: 6 %; mp: 254.5-257°C. IR (ATR): 3343, 1685, 1637, 1608, 1588, 1551, 1487, 1370, 
1332, 1307, 1295, 1243, 1196, 1184, 1152, 1101, 1081, 1066, 1017, 964, 879, 852, 824, 678. 
1
H NMR (500 
MHz, DMSO): δ 12.29 (1H, bs, OH), 10.74 (1H, s, NH), 9.90 (1H, s, COH), 8.40 (1H, d, J = 2.1 Hz, H6), 
7.97-7.93 (3H, m, H4, H3´, H5´), 7.74 (2H, d, J = 8.5 Hz, H2´, H6´), 7.17 (1H, d, J = 8.5 Hz, H3) 13C NMR 
(126 MHz, DMSO): δ 191.12, 165.60, 162.58, 142.13, 133.99, 132.86, 128.43, 126.26 (q, J = 3.8 Hz), 
124.52 (q, J = 272.0 Hz), 124.24 (q, J = 32.1 Hz), 120.57, 120.27, 118.01. Mwmonoizotopic (calc/meas): 309.1 / 
309.1. Anal. Calcd. for C15H10F3NO3 (309.24): C, 58.26; H, 3.26; N, 4.53;  Found: C, 58.34; H, 3.40; N, 4.48. 
 
4.1.1.2. Synthesis of the tuftsin derivatives 
General method of peptide synthesis 
The tuftsin derivatives with amide on the C-terminal were synthesised by solid-phase peptide 
synthesis on Fmoc-Rink Amide MBHA resin; in the case of tuftsin derivatives with carboxyl group on the C-
terminal Wang resin was used. The peptides were prepared in an automated peptide synthesizer (Syro-I, 
Biotage, Uppsala, Sweden) or manually using Fmoc/tBu strategy. In the case of the coupling of the first 
amino acid to the Wang resin 2 equiv. of Fmoc-amino acid derivative, 2 equiv. of DIC and 0.2 equiv. of 
DMAP (4-(dimethylamino)pyridine) dissolved in NMP was used (60 min). 
The protocol of the synthesis was the following: (i) Fmoc deprotection in the case of automated 
synthesizer with 20% piperidine/DMF (v/v), 2 min, 20 min; in the case of manual synthesis with 2% DBU, 
2% piperidine/DMF (v/v), 2 min, 2 min, 5 min, 10 min; (ii) washing with DMF (5 x 1 min); (iii) coupling 
twice with 4 equiv. of Fmoc-amino acid derivative−DIC−HOBt dissolved in NMP (2 x 60 min, automated 
synthesizer) or 3 equiv. of Fmoc-amino acid derivative−DIC−HOBt dissolved in NMP (1 x 60 min, manual 
synthesis); and (iv) washing with DMF (5 x 1 min).  
Peptides were cleaved from the resin with the TFA/H2O/TIS (9.5:2.5:2.5 v/v) mixture (2.5 h, RT). 
After filtration, compounds were precipitated in cold diethyl ether, centrifuged (4000 rpm, 5 min), and 
freeze-dried in water. Crude acetylated and 5(6)-carboxyfluorescein containing products were purified by 
semi-preparative RP-HPLC as described below. Purified peptides were analysed by analytical RP-HPLC, 
ESI-MS, and amino acid analysis. Crude Aoa-tuftsin derivatives were used for conjugation without 
purification. 
 
Synthesis of the tuftsin derivatives without side chain modification 
In the case of the tuftsin derivatives without any side chain modification Boc-Aoa-OH (3 equiv., DIC, 
HOBt, in NMP, 60 min) was coupled to the N-terminal of the peptides on the resin to get the 
(aminooxy)acetylated derivatives. The acetylated control peptides were produced by acetylation of the N-
terminal of the peptides on the resin using acetic anhydride/DIEA/DMF (1:1:2 v/v) for 60 min. In the case of 
labelling the N-terminal with 5(6)-carboxyfluorescein a mixture of 3 equiv. 5(6)-carboxyfluorescein, HOBt 
and DIC in NMP was added to the peptide-resin and after 60 min, the resin was washed and treated with 
20% piperidine in DMF for 5 and 30 min. This step is necessary because 5(6)-carboxyfluorescein contains 
unprotected hydroxyl group in the molecule, thus extra 5(6)-carboxyfluorescein molecules can couple to the 
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hydroxyl group of the 5(6)-carboxyfluorescein coupled directly to the peptide [59]. When these steps were 
not carried out, compounds containing two or three extra units of 5(6)-carboxyfluorescein were observed in 
the crude product. The peptides were cleaved from the resin as described above. 
 
Synthesis of the tuftsin derivatives with side chain modification 
In the case of the tuftsin derivatives with side chain modification Fmoc-Lys(Boc)-OH was replaced by 
Fmoc-Lys(Dde)-OH in the required position. After the final Fmoc-deprotection Boc-Aoa-OH (3 equiv., DIC, 
HOBt, in NMP, 60 min) or 5(6)-carboxyfluorescein (3 equiv., DIC, HOBt, in NMP 60 min, followed by 5 + 
30 min 20% piperidine treatment) was coupled to the N-terminal of the peptides. The acetylated peptides 
were produced by acetylation of the N-terminal using acetic anhydride/DIEA/DMF (1:1:2 v/v) for 60 min. 
After the derivatization of the N-terminal, the 1-(4,4-dimethyl-2,6-dioxocyclohex-1-yldine)ethyl (Dde) 
protecting group of the Lys side chain amino group was selectively removed using 2% hydrazine hydrate in 
DMF (v/v) (6 x 2 min), followed by washing with DMF (5 x 1 min). To the free ε-amino group of the Lys 
residue Boc-Aoa-OH or 5(6)-carboxyfluorescein or the appropriate fatty acid was coupled. In the case of 
butyric acid coupling of 3 equiv. of butyric anhydride, 3 equiv. of DIEA in DMF was used (60 min). In the 
case of decanoic acid and palmitic acid 3 equiv. of the corresponding fatty acid with 3 equiv. of HOBt, 3 
equiv. of DIC in NMP was used (60 min). The peptides were cleaved from the resin as described above. 
 
Synthesis of (aminooxy)acetyl-amino acid derivatives (Aoa-Thr-OH, Aoa-Gly-OH and H-Lys(Aoa)-
OH) 
Aoa-Thr-OH. Aoa-Gly-OH and H-Lys(Aoa)-OH were synthetized by solid-phase peptide synthesis on 
Wang resin manually using Fmoc/tBu strategy. Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH or Boc-Lys(Fmoc)-OH 
was coupled (2 equiv. of protected-amino acid derivative, 2 equiv. of DIC and 0.2 equiv. of DMAP, in NMP, 
60 min) to the resin, Fmoc protecting group was removed (2% DBU, 2% piperidine/DMF (v/v), 2, 2, 5, 10 
min) and Boc-Aoa-OH was coupled (3 equiv., DIC, HOBt, in NMP, 60 min). The (aminooxy)acetyl amino 
acid derivatives were cleaved from the resin with the TFA/H2O/TIS (9.5:2.5:2.5 v/v) mixture (2.5 h, RT). 
After filtration, majority of the TFA was removed by rotary evaporation, and the crude product was freeze-
dried in water. Crude Aoa-amino acid derivatives were used for conjugation without purification. 
 
Reverse-Phase High-Performance Liquid Chomatography (RP-HPLC) 
Analytical RP-HPLC was performed on Exformma HPLC system (Wufeng Scientific Instrument, 
Sanghai, China) using an Agilent Zorbax SB-C18 column (5 μm, 100 Å, 4.6 mm x 150 mm) (Agilent 
Technologies, Santa Clara, CA, United States). Gradient elution (0-5 min 0% B, 5-15 min 0-60% B, 15-25 
min 60-100% B, 25-29 min 100% B) was used with the following eluents: 0.1% TFA/water v/v (A eluent), 
0.1% TFA/acetonitrile-water 80:20 v/v (B eluent). The flow rate was 1 mL/min at ambient temperature, and 
the peaks were detected at 220 nm. 
The crude peptides and conjugates were purified on a semi-preparative Phenomenex Jupiter Proteo 
C18 column (10 μm, 90 Å, 10 x 250 mm) (Torrance, CA, USA). The applied flow rate was 4 mL/min at 
ambient temperature, and the peaks were detected at 220 nm. The same eluents as described above with an 
appropriate linear gradient were applied. 
 
Electrospray Ionization Mass Spectrometry (ESI-MS)  
ESI-MS was performed on a Bruker Esquire 3000+ ion trap mass spectrometer (Bremen, Germany), 
operating in continuous sample injection mode at 10 μL/min flow rate. Samples were dissolved in 50% 
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acetonitrile/50% water containing 0.1% acetic acid (v/v). Mass spectra were recorded in positive or negative 
ion mode in the m/z 50-1500 range. 
 
4.1.1.3. Conjugation of salicylanilides to tuftsin derived carrier peptides 
Salicylanilide compounds, which contain carbonyl group, were conjugated to the 
(aminooxy)acetylated tuftsin derivatives. The conjugations via oxime bond were carried out under acidic 
condition (pH 4.5) in a mixture of 0.2 M sodium acetate buffer and 2-methoxyethanol, at a peptide 
concentration of 5-10 mg/mL. Salicylanilide derivatives were used in 10% excess as compared to the 
(aminooxy)acetyl derivatives of the tuftsin peptides. The reaction mixtures were stirred for 24-72 h at room 
temperature and monitored by analytical RP-HPLC. The conjugates were purified by semi-preparative RP-
HPLC and lyophilized. The purified conjugates were characterized by analytical RP-HPLC and mass 
spectrometry. 
 
4.2. Determination of in vitro antimycobacterial activity  
In vitro antimycobacterial activity of the compounds was determined on slow growing Mycobacterium 
tuberculosis H37Rv (ATCC 27294) and Mycobacterium tuberculosis A8 MDR strain (ATCC 35822, resistant 
to isoniazid, and rifampicin), and on fast growing Mycobacterium abscessus strain (ATCC 19977), by serial 
dilution in Sula semisynthetic medium, which was prepared in-house (pH 6.5) [60, 61]. Compounds were 
added to the medium as DMSO solutions at various doses (range of final concentration was between 0.05 
and 400 μg/mL). Minimal inhibitory concentrations (MIC) were determined after incubation at 37 °C for 21 
or 28 days in the case of M. tuberculosis H37Rv, for 28 days in the case of A8 MDR, and for 7 days in the 
case of M. abscessus. MIC was the lowest concentration of a compound at which the visible inhibition of the 
growth of M. abscessus, M. tuberculosis H37Rv and A8 MDR strain occurred. In order to confirm the growth 
inhibition, colony forming unit (CFU, the number of the colonies that developed from the viable bacteria) 
was determined by subculturing from the Sula medium onto drug-free Löwenstein-Jensen solid medium. 
Samples were incubated for further 28 days in the case of M. tuberculosis H37Rv and A8 MDR, and for 7 
days in the case of M. abscessus. Experiments were repeated at least two times. Isoniazid (INH), gentamicin 
(GEN) and ciprofloxacin (CIPX) were involved as reference antimycobacterial drugs. 
 
4.3. Determination of in vitro cytostatic and cytotoxic activity 
The in vitro cytostatic activity of the compounds was determined on MonoMac6 and HepG2 cells. 
MonoMac6 cell cultures (DSMZ no.: ACC 124, Deutsche Sammlung von Mikroorganismen and 
Zellkulturen GmbH, Braunschweig, Germany) and HepG2 cell cultures (ATCC HB-8065) were maintained 
in RPMI-1640 medium containing 10% FCS, 2 mM L-glutamine, and 160 μg/mL gentamicin at 37 °C in 5% 
CO2 atmosphere. The cells were plated on 96-well plates one day before the treatment (5000 cells/1 mL 
medium/well). After 24 h incubation at 37 °C, cells were treated for 24 h (overnight) with the compounds 
dissolved in serum free RPMI-1640 medium (cDMSO = 1.0% v/v) at 1×10
-3
 to 200 µM concentration range. 
Control cells were treated with serum free medium only or with DMSO containing serum free medium 
(cDMSO = 1.0% v/v) at 37 °C. After the treatment and incubation, cells were washed twice with serum free 
medium (centrifugation: 1000 rpm, 5 min). To determine the in vitro cytostatic effects, the cells were 
cultured for a further 72 h in serum containing medium. The cell viability was determined with (4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-assay. 45 μL MTT solution (2 mg/mL) was 
added to each well (final concentration 367 μg/mL) and during 3.5 h incubation purple formazan crystals 
were formed by mitochondrial dehydrogenase enzyme present in the living cells. After incubation cells were 
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centrifuged for 5 min at 2000 rpm and the supernatant was removed. The obtained formazan crystals were 
dissolved in DMSO and the optical density (OD) of the samples was determined at λ= 540 and 620 nm using 
an ELISA Reader (Labsystems iEMS reader, Helsinki, Finland). The OD620 values were subtracted from the 
OD540 values. The percent of cytostasis was calculated using the following equation: ‘cytostatic effect (%) = 
100 × [1-(ODtreated/ODcontrol)]’, where ODtreated and ODcontrol correspond to the optical densities of treated and 
control cells, respectively. In each case two independent experiments were carried out with 4 parallel 
measurements. The 50% inhibitory concentration (IC50) values were determined from the dose-response 
curves. The curves were defined using Microcal
TM
 Origin1 (version 7.5) software. 
The in vitro cytotoxic activity of the selected compounds was determined on murine bone marrow-
derived macrophages (BMMΦ). The cells were prepared and differentiated as described in the literature [62], 
licence: XIV-I-001/2149-4/2012. The cells were plated on 96-well plates one day before the treatment (10 
000 cells/1 mL medium/well). After 24 h incubation at 37 °C, cells were treated for 48 h with the compounds 
dissolved in serum free RPMI-1640 medium (cDMSO = 1.0% v/v) at 1×10
-3
 to 100 µM concentration range. 
Control cells were treated with serum free medium only or with DMSO containing serum free medium 
(cDMSO = 1.0% v/v) at 37 °C. After the treatment and incubation, cells were washed twice with serum free 
medium (centrifugation: 1000 rpm, 5 min). To measure the in vitro cytotoxicity of the compounds, the MTT 
assay (as described above) was performed immediately after the washing step following the 48 h treatment.  
 
4.4. Determination of the pH dependence of the fluorescence intensity of the fluorescently labelled 
tuftsin derivatives 
Prior to the cellular uptake studies the pH dependence of the fluorescence intensity of the fluorescently 
labelled tuftsin derivatives was studied using Varian Cary Eclipse Fluorescence Spectrophotometer (Agilent 
Technologies, Santa Clara, CA, USA). Stock solutions in distilled water with 5 mM compound concertation 
were prepared and then diluted to 50 μM with the appropriate citric acid – Na2HPO4 buffer in a 3 mL 
cuvette. In the case of Cf-T5(4-pal) that has poor solubility in water 2.5 mM stock solution was prepared 
with DMSO : distilled water 1:1 v/v, after dilution the final DMSO content was 1% v/v.  Five solutions with 
different pH values were used (pH 4, 5, 6, 7 and 7.6). Supporting Information Table S6 shows the volumes 
of the 0.1 M citric acid and 0.2 M Na2HPO4 that were needed for the preparation of the buffers with different 
pH. As excitation wavelength 488 nm was used and the emission was measured between 490 and 700 nm, 
450 V detector voltage was used.   
 
4.5. Cellular uptake experiments 
The measurement of cellular uptake of the fluorescently labelled tuftsin derivatives was evaluated by 
flow cytometry (BD LSR II, BD Biosciences, San Jose, CA, USA) and fluorescent microscopy (Olympus 
CKX41, Hamburg, Germany, Olympus U-RFLT50 mercury-vapor lamp, WideBlue DM500 BP460-490 
BA520 IF filter, objective: 40X) on MonoMac6 human monocytic cell line. Cells were harvested in the 
logarithmic phase of growth and plated on a 24-well tissue culture plate (10
5
 cells/1 mL medium/well) 24 
hours prior to the experiment. Fluorescently labelled tuftsin derivatives were dispersed in serum free RPMI 
medium and running dilutions were prepared. Applied concentration of the compounds on the cells was 0.32, 
1.6, 8, 40 and 200 μM. Cells were incubated with compounds for 3 h (37 °C, 5% CO2 atmosphere). After 
centrifugation (1000 rpm, 5 min) supernatant was removed and 100 μL 1 mM trypsin was added to the cells. 
After 1 min incubation at 37 °C the effect of trypsin was stopped by 800 μL HPMI medium (HPMI; 100 mM 
NaCl, 5.4 mM KCl, 0.4 mM MgCl2, 0.04 mM CaCl2, 10 mM HEPES, 20 mM glucose, 24 mM NaHCO3 and 
5 mM Na2HPO4 at pH = 7.4) containing 10% FCS, and the cells were transferred from the plate to FACS-
 38 
 
tubes. Cells were centrifuged (1000 rpm, 5 min) and the supernatant was removed. After this procedure, cells 
were resuspended in 500 μL HPMI, and the intracellular fluorescence intensity of MonoMac6 cells was 
measured (488 nm (Coherent Sapphire, 22 mW) laser, channel PE LP550 (emission at λ = 550 nm)) which is 
proportional to the cellular uptake. Data were analysed with FACSDiva 5.0 software (BD Biosciences, San 
Jose, CA, USA). All measurements were performed in duplicates. Parallel with flow cytometry 
measurements microscopic image of the cells were captured with an Olympus CKX41 microscope. 
The cellular uptake of the fluorescently labelled tuftsin derivatives was also studied on murine bone 
marrow-derived macrophages (BMMΦ). The cells were prepared and differentiated as described in the 
literature [62], licence: XIV-I-001/2149-4/2012. The steps of the protocol of the uptake study are the same as 
described above.  
 
4.6. Membrane integrity studies by propidium iodide staining 
PI staining was used to compare the effect of the control tuftsin peptides with or without fatty acid side 
chains (Ac-OT20, Ac-OT20(4-dec), Ac-OT20(4-pal) and Ac-OT20(14-pal)) to the cell membrane integrity 
using flow cytometry and fluorescent microscopy on MonoMac6 human monocytic cell line. Cells were 
harvested in the logarithmic phase of growth and plated on a 24-well tissue culture plate (10
5
 cells/1 mL 
medium/well) 24 hours prior to the experiment. Acetylated tuftsin derivatives were dispersed in serum free 
RPMI medium and running dilutions were prepared. Applied concentration of the compounds on the cells 
was 8, 40 and 200 μM. Cells were incubated with compounds for 3 h (37 °C, 5% CO2 atmosphere). After 
centrifugation (1000 rpm, 5 min) supernatant was removed and 100 μL 1 mM trypsin was added to the cells. 
After 1 min incubation at 37 °C the effect of trypsin was stopped by 800 μL HPMI containing 10% FCS, and 
the cells were transferred from the plate to FACS-tubes. Cells were centrifuged (1000 rpm, 5 min) and the 
supernatant was removed. After this procedure, cells were resuspended in 500 μL HPMI. The cell viability 
and intracellular fluorescence intensity of MonoMac6 cells was determined by BD LSR II (488 nm 
(Coherent Sapphire, 22 mW) laser, channel PE LP550 (emission at λ = 550 nm)) before and after adding 10 
μL 50 μg/mL propidium-iodide solution. Data were analysed with FACSDiva 5.0 software. All 
measurements were performed in duplicates. Parallel with flow cytometry measurements microscopic image 
of the cells were captured with an Olympus CKX41 microscope (Olympus U-RFLT50 mercury-vapor lamp, 
SuperWideGreen DM570 BP480-550 BA590 IF filter, objective: 40X). 
 
4. 7. Degradation of SAL2-tuftsin conjugates in rat liver lysosomal homogenate and HPLC-MS 
analysis 
The rat liver lysosomal homogenate was prepared as described previously [56]. The protein 
concentration was determined by Pierce BCA protein assay (bicinchoninic acid) according to the 
manufacturer’s protocol (Thermo Fisher Scientific, Rockford, IL, USA) and it was 16.6 μg/μL. 
The degradation of the SAL2-tuftsin conjugates in the rat liver lysosomal homogenate was determined 
as follows: 90 μL of 50 μM (50 pmol/μL) conjugate solutions were prepared with 0.2 M sodium acetate 
buffer, pH 5.0 and the appropriate amount of lysosomal homogenate was added to them to get the 
conjugates: lysosomal homogenate ratio = 1:1, w/w. The reaction mixtures were incubated at 37 °C and 
aliquots of 13 μL were taken at 5 min, 1, 2, 4, 8 and 24 h. The reactions were quenched by adding 2 μL of 
acetic acid and followed by HPLC-MS analysis. Control experiments were performed with solutions of 
conjugates in 0.2 M sodium acetate buffer, pH 5 with 50 μM conjugate concentration, which were incubated 
at 37 °C for 24 h and then also analysed by HPLC-MS. Lysosomal homogenate control in 0.2 M sodium 
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acetate buffer, pH 5 without conjugate was also performed, the solution was incubated at 37 °C for 24 h and 
also analysed by HPLC-MS. 
  High performance liquid chromatography–mass spectrometry (HPLC-MS) was carried out on an 
Esquire 3000 + ion trap mass spectrometer (Bruker Daltonics, Bremen, Germany) equipped with a Jasco LC-
2000Plus HPLC system (Jasco Europe, Cremella, Italy). Compounds were separated on a Supelco Ascentis 
C18 column (3 μm, 100 Å, 150 x 2.1 mm; Sigma-Aldrich) using a gradient elution (0-5 min 2% B, 5-26 min 
2-90% B, 26-27 min 90-100% B) with the following eluents: 0.1% formic acid/water v/v (A eluent), 0.1% 
formic acid/acetonitrile-water 80:20 v/v (B eluent). The flow rate was 0.2 mL/min at ambient temperature. 
Spectra were recorded in positive ion mode in the 150–1200 m/z range (target mass set 500 m/z).  
 
4.5. Determination of intracellular antitubercular activity 
MonoMac6 cells were infected with M. tuberculosis H37Rv and the efficacy of the compounds against 
intracellular bacteria was determined [38, 42]. MonoMac6 human monocytic cell line was maintained in 
RPMI-1640 medium containing 10% FCS, 2 mM L-glutamine and 160 μg/mL gentamicin at 37 °C in 5% 
CO2 atmosphere. Prior to experiment, cells were cultured in a 24-well plate for 24 hours (2×10
5
 cells/1 mL 
medium/well). Adherent cells were infected with M. tuberculosis H37Rv at a multiplicity of infection (MOI) 
of 10 for 4 hours. Non-phagocytized extracellular bacteria were removed and the culture was washed three 
times with serum free RPMI-1640. The infected monolayer was incubated for 1 day before antitubercular 
treatment. Infected cells were then treated with the compounds at 125 and 250 μM final concentrations. After 
3 days the treatment was repeated with fresh solution of the compounds for an additional 3 days. As control 
compound, isoniazid was used at 50 μg/mL (365 μM) concentration. Untreated cells were considered as 
negative control. After washing steps, in order to remove the compounds, infected cells were lysed with 
2.5% sodium dodecyl sulfate solution. The CFU of M. tuberculosis H37Rv was enumerated on Löwenstein-
Jensen solid media after 4 weeks of incubation. Experiments were repeated at least twice. 
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